Arcadia Biosciences (RKDA) 10-K31 Mar 212020 FY Annual reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2020	Mar. 19, 2021	Jun. 30, 2020
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Registrant Name	Arcadia Biosciences, Inc.
Entity Central Index Key	0001469443
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding		21,336,249
Entity Public Float			$ 33,300,000
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Small Business	true
Entity File Number	001-37383
Entity Tax Identification Number	81-0571538
Entity Address, Address Line One	202 Cousteau Place
Entity Address, Address Line Two	Suite 105
Entity Address, City or Town	Davis
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95618
City Area Code	530
Local Phone Number	756-7077
Entity Incorporation, State or Country Code	DE
Trading Symbol	RKDA
Title of 12(b) Security	Common
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Document Annual Report	true
Document Transition Report	false
ICFR Auditor Attestation Flag	false
Documents Incorporated by Reference	Information required by Part III of this Annual Report on Form 10-K is incorporated by reference to the Registrant's Definitive Proxy Statement for its 2021 Annual Meeting of Stockholders, which proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year covered by this Form 10-K.

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 14,042	$ 8,417
Short-term investments	11,625	16,915
Accounts receivable	1,406	602
Inventories, net — current	3,812	1,794
Prepaid expenses and other current assets	811	712
Total current assets	31,696	28,440
Restricted cash	2,001
Property and equipment, net	3,539	1,799
Right of use assets	5,826	1,963
Inventories, net — noncurrent	3,485	364
Goodwill	408
Intangible assets, net	370
Other noncurrent assets	23	8
Total assets	47,348	32,574
Current liabilities:
Accounts payable and accrued expenses	4,105	4,685
Amounts due to related parties	80	40
Debt - current	1,141	24
Unearned revenue — current	8	42
Operating lease liability - current	717	611
Other current liabilities	263	306
Total current liabilities	6,314	5,708
Debt - noncurrent	2,105	107
Operating lease liability - noncurrent	5,389	1,497
Common stock warrant liabilities	2,708	14,936
Other noncurrent liabilities	2,280	2,000
Total liabilities	18,796	24,248
Commitments and contingencies (Note 15)
Stockholders’ equity:
Common stock, $0.001 par value—150,000,000 shares authorized as of December 31, 2020 and December 31, 2019; 13,450,861 and 8,646,149 shares issued and outstanding as of December 31, 2020 and December 31, 2019, respectively.	54	49
Additional paid-in capital	239,496	214,826
Accumulated other comprehensive income		1
Accumulated deficit	(211,825)	(207,171)
Total Arcadia Biosciences stockholders’ equity	27,725	7,705
Non-controlling interest	827	621
Total stockholders' equity	28,552	8,326
Total liabilities and stockholders’ equity	$ 47,348	$ 32,574

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	150,000,000	150,000,000
Common stock, issued	13,450,861	8,646,149
Common stock, outstanding	13,450,861	8,646,149

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenues:
Total revenues	$ 8,034,000	$ 1,169,000
Operating expenses (income):
Research and development	7,960,000	7,098,000
Gain on sale of Verdeca	(8,814,000)
Change in fair value of contingent consideration		(1,000,000)
Selling, general and administrative	16,467,000	13,567,000
Total operating expenses	20,812,000	20,550,000
Loss from operations	(12,778,000)	(19,381,000)
Interest expense	(47,000)	(5,000)
Other income, net	740,000	466,000
Change in fair value of common stock warrant liabilities	6,570,000	(9,243,000)
Loss on extinguishment of warrant liability	(635,000)
Offering costs		(708,000)
Net loss before income taxes	(6,150,000)	(28,871,000)
Income tax benefit (provision)	124,000	(2,000)
Net loss	(6,026,000)	(28,873,000)
Net loss attributable to non-controlling interest	(1,371,000)	(68,000)
Net loss attributable to common stockholders	$ (4,655,000)	$ (28,805,000)
Net loss per share attributable to common stockholders:
Basic and diluted	$ (0.47)	$ (4.53)
Weighted-average number of shares used in per share calculations:
Basic and diluted	9,959,018	6,363,112
Other comprehensive (loss) income, net of tax
Unrealized (losses) gains on investment securities	$ (1,000)	$ 1,000
Other comprehensive (loss) income	(1,000)	1,000
Comprehensive loss attributable to common stockholders	(4,656,000)	(28,804,000)
Product
Revenues:
Total revenues	1,044,000	814,000
Operating expenses (income):
Cost of product revenues	5,199,000	885,000
License
Revenues:
Total revenues	6,801,000	67,000
Royalty
Revenues:
Total revenues	83,000
Contract Research And Government Grants
Revenues:
Total revenues	$ 106,000	$ 288,000

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	December 2020 Offering [Member]	June 2019 Offering [Member]	September 2019 Offering [Member]	June 2018 Warrants [Member]	May 2020 Warrants Transaction [Member]	May 2020 Warrants [Member]	March 2018 PIPE [Member]	July 2020 Warrants Transaction [Member]	July 2020 Warrants [Member]	Common Stock [Member]	Common Stock [Member]December 2020 Offering [Member]	Common Stock [Member]June 2019 Offering [Member]	Common Stock [Member]September 2019 Offering [Member]	Common Stock [Member]June 2018 Warrants [Member]	Common Stock [Member]March 2018 PIPE [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member]December 2020 Offering [Member]	Additional Paid-In Capital [Member]June 2019 Offering [Member]	Additional Paid-In Capital [Member]September 2019 Offering [Member]	Additional Paid-In Capital [Member]June 2018 Warrants [Member]	Additional Paid-In Capital [Member]May 2020 Warrants Transaction [Member]	Additional Paid-In Capital [Member]May 2020 Warrants [Member]	Additional Paid-In Capital [Member]March 2018 PIPE [Member]	Additional Paid-In Capital [Member]July 2020 Warrants Transaction [Member]	Additional Paid-In Capital [Member]July 2020 Warrants [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive (Loss) Income [Member]	Non-controlling Interest [Member]
Stockholders Equity, Beginning Balance at Dec. 31, 2018	$ 12,815										$ 45						$ 191,136										$ (178,366)
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2018											4,774,919
Issuance of shares related to employee stock purchase plan	18																18
Issuance of shares related to employee stock purchase plan, Shares											8,536
Issuance of shares related to employee stock option exercises	$ 3																3
Issuance of shares related to employee stock option exercises, Shares	546										546
Issuance of shares and warrants			$ 3,303	$ 6,571									$ 2	$ 1					$ 3,301	$ 6,570
Issuance of shares and warrants, Shares													1,489,575	1,318,828
Offering costs			(489)	(808)															(489)	(808)
Issuance of placement agent warrants			198	$ 326															198	$ 326
Issuance of shares related to the exercise of warrants			$ 5,269										$ 1						$ 5,268
Issuance of shares related to the exercise of warrants, Shares													1,053,745
Reclassification of common stock warrant liability balance with exercise	$ 7,016																7,016
Stock-based compensation	2,287																2,287
Non-controlling interest contributions	689																												$ 689
Unrealized (losses) gains on investment securities	1																											$ 1
Net loss	(28,873)																										(28,805)		(68)
Stockholders Equity, Ending Balance at Dec. 31, 2019	8,326										$ 49						214,826										(207,171)	1	621
Stockholders Equity, Ending Balance, Shares at Dec. 31, 2019											8,646,149
Issuance of shares related to employee stock purchase plan	51																51
Issuance of shares related to employee stock purchase plan, Shares											19,667
Issuance of shares					$ 5,569			$ 2,444							$ 1	$ 1					$ 5,568			$ 2,443
Issuance of shares, Shares															1,392,345	641,416
Issuance of shares and warrants		$ 8,000										$ 3						$ 7,997
Issuance of shares and warrants, Shares												2,618,658
Offering costs		(939)																(939)
Issuance of investor warrants						$ 4,415			$ 2,059													$ 4,415			$ 2,059
Issuance of placement agent warrants		$ 287					$ 215			$ 101								$ 287					$ 215			$ 101
Shares of common stock issued at closing of ISI transaction	432																432
Shares of common stock issued at closing of ISI transaction, Shares											132,626
Stock-based compensation	2,042																2,042
Non-controlling interest contributions	1,578																												1,578
Unrealized (losses) gains on investment securities	(1)																											$ (1)
Net loss	(6,026)																										(4,655)		(1,371)
Stockholders Equity, Ending Balance at Dec. 31, 2020	$ 28,552										$ 54						$ 239,496										$ (211,825)		$ 827
Stockholders Equity, Ending Balance, Shares at Dec. 31, 2020											13,450,861

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2020	Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (6,026,000)	$ (28,873,000)
Adjustments to reconcile net loss to cash used in operating activities:
Change in fair value of common stock warrant liabilities	(6,570,000)	9,243,000
Change in fair value of contingent consideration		(1,000,000)
Offering costs		708,000
Depreciation	632,000	194,000
Amortization of intangible assets	30,000
Lease amortization	1,048,000	708,000
(Gain) Loss on disposal of equipment	(8,000)	3,000
Net amortization of investment premium	(44,000)	(180,000)
Stock-based compensation	2,042,000	2,287,000
Gain on sale of Verdeca	(8,814,000)
Corporate securities received in exchange for license agreement	(4,318,000)
Unrealized gain on corporate securities	(656,000)
Write down of inventory	4,311,000	304,000
Loss on extinguishment of warrant liability	635,000
Deferred income taxes	(107,000)
Changes in operating assets and liabilities:
Accounts receivable	(1,119,000)	(437,000)
Unbilled revenue		3,000
Inventories	(9,751,000)	(1,535,000)
Prepaid expenses and other current assets	39,000	(8,000)
Other noncurrent assets	(15,000)	(1,000)
Accounts payable and accrued expenses	(580,000)	2,102,000
Amounts due to related parties	40,000	11,000
Unearned revenue	(34,000)	(54,000)
Other current liabilities	(43,000)	42,000
Operating lease payments	(910,000)	(715,000)
Net cash used in operating activities	(30,218,000)	(17,198,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of property and equipment	8,000	16,000
Purchases of property and equipment	(2,335,000)	(1,477,000)
Proceeds from sale of Verdeca	3,153,000
Acquisitions, net of cash acquired	(500,000)
Purchases of investments	(1,292,000)	(28,358,000)
Proceeds from sales and maturities of investments	18,250,000	21,450,000
Net cash provided by (used in) investing activities	17,284,000	(8,369,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from borrowings	3,108,000
Payments of transaction costs relating to extinguishment of warrant liability	(863,000)
Principal payments on notes payable	(34,000)	(8,000)
Proceeds from exercise of warrants	9,372,000	5,269,000
Proceeds from exercise of stock options and purchases through ESPP	51,000	21,000
Capital contributions received from non-controlling interest	1,578,000	689,000
Net cash provided by financing activities	20,560,000	21,986,000
Net increase (decrease) in cash, cash equivalents and restricted cash	7,626,000	(3,581,000)
Cash, cash equivalents and restricted cash — beginning of period	8,417,000	11,998,000
Cash, cash equivalents and restricted cash — end of period	16,043,000	8,417,000
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	10,000	4,000
Cash paid for taxes	1,000	2,000
NONCASH TRANSACTIONS:
Offering costs in accounts payable and accrued expenses at end of period		20,000
Shares of common stock issued at closing of ISI transaction	432,000
Reclassification of common stock warrant liability balance with warrant exercises		7,016,000
Right of use assets obtained in exchange for new operating lease liabilities	331,000	2,328,000
Right of use assets obtained through modification of existing lease agreement	4,207,000	194,000
Fixed assets acquired with notes payable	37,000	139,000
Purchases of fixed assets included in accounts payable and accrued expenses	71,000	1,000
December 2020 Purchase Agreement [Member]
NONCASH TRANSACTIONS:
Common stock warrants issued to placement agent and included in offering costs related to purchase agreement	287,000
May 2020 Warrants Transaction [Member]
NONCASH TRANSACTIONS:
Common stock warrants issued to placement agent and included in offering costs	215,000
July 2020 Warrants Transaction [Member]
NONCASH TRANSACTIONS:
Common stock warrants issued to placement agent and included in offering costs	101,000
June 2019 Offering [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of offering costs		(663,000)
Proceeds from issuance of common stock and warrants from Offering		7,500,000
NONCASH TRANSACTIONS:
Common stock warrants issued to placement agent and included in offering costs		86,000
September 2019 Offering [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of offering costs		(798,000)
Proceeds from issuance of common stock and warrants from Offering		10,000,000
NONCASH TRANSACTIONS:
Common stock warrants issued to placement agent and included in offering costs		95,000
June 2018 Offering [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of offering costs		$ (24,000)
December 2020 Offering [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of offering costs	(652,000)
Proceeds from issuance of common stock and warrants from Offering	$ 8,000,000

Description of Business

Description of Business	12 Months Ended
Description of Business	Dec. 31, 2020
Accounting Policies [Abstract]
Description of Business	Note 1. Description of Business Organization Arcadia Biosciences, Inc. (the "Company"), was incorporated in Arizona in 2002 and maintains its headquarters in Davis, California, with additional facilities in Phoenix, Arizona, American Falls, Idaho, Molokai, Hawaii, and Albany, Oregon. The Company was reincorporated in Delaware in March 2015. The Company is a leader in science-based approaches to developing high value crop productivity traits primarily in hemp, wheat, and soybean, designed to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. The Company uses state of the art gene-editing technology and advanced breeding techniques to develop these proprietary innovations which the Company is beginning to monetize through a number of methods including seed and grain sales, product extract sales, trait licensing and royalty agreements. In February 2012, the Company formed Verdeca LLC (“Verdeca,” see Note 9), a limited liability company jointly owned with Bioceres, Inc. (“Bioceres”), a U.S. wholly owned subsidiary of Bioceres, S.A., an Argentine corporation. Bioceres, S.A. is an agricultural investment and development cooperative. On November 12, 2020, the Company entered into a Master Transaction Agreement (“Transaction”) with Bioceres Crop Solutions Corp pursuant to which the Company sold all of its memberships interests it owned in Verdeca to Bioceres, Inc. Verdeca was consolidated by the Company through the date of the Transaction. On August 9, 2019, the Company entered into a joint venture agreement with Legacy Ventures Hawaii, LLC (“Legacy,” see Note 8) to grow, extract, and sell hemp products. The new partnership, Archipelago Ventures Hawaii, LLC (“Archipelago”), combines the Company’s extensive genetic expertise and resources with Legacy’s experience in hemp extraction and sales. Liquidity, Capital Resources, and Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. Since inception, the Company has financed its operations primarily through equity and debt financings. As of December 31, 2020, the Company had an accumulated deficit of $211.8 million, cash and cash equivalents of $14.0 million, restricted cash of $2.0 million, and short-term investments of $11.6 million. For the years ended December 31, 2020 and 2019, the Company had net losses of $6.0 million and $28.9 million, respectively, and net cash used in operations of $30.2 million and $17.2 million, respectively. The Company believes that its existing cash, cash equivalents and investments will be sufficient to meet its anticipated cash requirements for at least through March 2022. The Company may seek to raise additional The Company is closely monitoring how the spread of the novel coronavirus (“COVID-19”) is affecting its business operations and employees. The Company’s targeted revenues have been adversely impacted as hemp growers have been slower to make decisions to purchase hemp seeds due to economic uncertainty and wheat consumer packaged goods companies have been heavily focused on production over R&D evaluation as demand for staples like pasta and flour have increased. The continued spread of the outbreak may further impact the Company’s business, results of operations, and financial condition.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The consolidated financial statements include the accounts of the Company, Verdeca and Archipelago. All intercompany balances and transactions have been eliminated in consolidation. The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP (“GAAP”), and with the rules of the Securities and Exchange Commission. The Company uses a qualitative approach in assessing the consolidation requirement for variable interest entities ("VIEs"). This approach focuses on determining whether the Company has the power to direct the activities of the VIE that most significantly affect the VIE’s economic performance and whether the Company has the obligation to absorb losses, or the right to receive benefits, that could potentially be significant to the VIE. Up to the date of the sale transaction described in Note 1, the Company has determined that it is the primary beneficiary of Verdeca, which was a VIE. Accordingly, the Company consolidates Verdeca in the consolidated financial statements after eliminating intercompany transactions. The Company evaluates its relationships with its VIEs upon the occurrence of certain significant events that affect the design, structure or other factors pertinent to the primary beneficiary determination. Verdeca had no operations, assets or liabilities as of and for the period ended November 12, 2020 and for the year ended December 31, 2019. For all periods presented, the Company has determined that it is the primary beneficiary of Archipelago, a joint venture, as it has a controlling interest in Archipelago. Accordingly, the Company consolidates Archipelago in the consolidated financial statements after eliminating intercompany transactions. For consolidated joint ventures, the non-controlling partner’s share of the assets, liabilities and operations of the joint venture is included in non-controlling interests as equity of the Company. The non-controlling partner’s interest is generally computed as the joint venture partner’s ownership percentage of Archipelago. Net loss attributable to non-controlling interest of $1,371,000 and $68,000 is recorded as an adjustment to net loss to arrive at net loss attributable to common stockholders for the years ended December 31, 2020 and 2019, respectively. The non-controlling partner’s equity interests are presented as non-controlling interests on the consolidated balance sheets as of December 31, 2020 and 2019. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions in the Company’s consolidated financial statements and notes thereto. Significant estimates and assumptions made by management included the determination of the provision for income taxes, stock-based compensation, fair value of certain equity instruments, and net realizable value of inventory. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. COVID-19 continues to create significant uncertainty and disruption in the global economy and financial markets and could impact estimates. Cash and Cash Equivalents The Company considers any liquid investments with a stated maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents consist of cash on deposit with banks. The Company limits cash investments to financial institutions with high credit standings; therefore, management believes that there is no significant exposure to any credit risk in the Company’s cash and cash equivalents. However, as of December 31, 2020 and 2019, a substantial portion of the Company’s cash in depository accounts is in excess of the federal deposit insurance limits. Restricted Cash Restricted cash consists of funds that are contractually or legally restricted as to usage or withdrawal and have been presented separately from cash and cash equivalents on the consolidated balance sheets Investments in Debt and Equity Securities Investments in debt and equity securities are carried at fair value and classified as short-term investments. The 1,875,000 shares of common stock of Bioceres Crop Solutions Corp. (“BIOX”) added during the fourth quarter ended December 31, 2020, have a six-months’ trading restriction, expiring on May 12, 2021. Realized and unrealized gains and losses on investment securities are included in other income, net, in the consolidated statements of operations and comprehensive loss. Investment securities are reported as cash and cash equivalent, short-term investments or long-term investments in the consolidated balance sheets based on the nature of the investments and maturity period. Short-term investments have maturities of less than a year and long-term investments have maturities of a year and greater from the balance sheet date. The Company’s equity securities are primarily comprised of shares of BIOX listed on the New York Stock Exchange (“NYSE”). These investments are held in the custody of a major financial institution. Other debt securities consist of U.S. government securities, treasury bills, commercial paper, corporate securities, and money markets. Other-than-Temporary Impairments on Investment The Company regularly reviews each of its investments for impairment by determining if the investment has sustained an other-than-temporary decline in its value, in which case the investment is written down to its fair value by a charge to earnings. Factors that are considered by the Company in determining whether an other-than-temporary decline in value has occurred include (i) the market value of the investment in relation to its cost basis, (ii) the financial condition of the investment, and (iii) the Company’s intent and ability to retain the investment for a sufficient period of time to allow for recovery of the market value of the investment. As of December 31, 2020 and 2019, there was no impairment of the Company’s investments. Accounts Receivable Accounts receivable represents amounts owed to the Company from product sales, licenses, royalties and contract research and government grants. The carrying value of the Company’s receivables represents estimated net realizable values. The Company generally does not require collateral and estimates any required allowance for doubtful accounts based on historical collection trends, the age of outstanding receivables, and existing economic conditions. If events or changes in circumstances indicate that specific receivable balances may be impaired, further consideration is given to the collectability of those balances and the allowance is recorded accordingly. Past-due receivable balances are written off when the Company’s internal collection efforts have been unsuccessful in collecting the amounts due. The Company had no amounts reserved for doubtful accounts at December 31, 2020 and 2019 as the Company expected full collections of all accounts receivable balances as of each of these dates. Inventory GoodWheat: Propriety wheat plants are grown, producing seed with a variety of improved nutritional qualities, including high levels of amylose, improved shelf-life, and reduced gluten. The seed is used for subsequent plantings or processed, and sold as GoodWheat seeds, grain, and flour, which the Company refers to collectively as GoodWheat products. Amounts inventoried consist primarily of fees paid to contracted cooperators to grow the crops, costs to process and store harvested seed and grain, and costs to mill the grain into flour. SONOVA® Gamma Linolenic Acid (“GLA”) Safflower Oil: Proprietary safflower plants were grown, producing seed with a high-GLA content. This seed was processed, and is sold as GLA oil, including SONOVA 400 GLA safflower oil and SONOVA Ultra GLA safflower oil, which the Company refers to collectively as SONOVA products. Amounts inventoried consist primarily of fees paid to contracted cooperators to grow the crops and costs to process and store the oil. GoodHemp : Proprietary seeds are grown and used for subsequent plantings and sold as final product to other growers. Amounts in inventory for internally produced hemp seeds consist primarily of labor, supplies and facility costs. The costs to procure seeds from external growers and suppliers are included in inventory, as well. Archipelago : Hemp seeds are purchased from external sources and planted on land leased in Molokai. The costs of purchasing, planting and growing the seed, and harvesting the resulting biomass are captured as inventory, along with the costs to process the biomass into CBD oil. Amounts in inventory for growing biomass primarily consist of labor, supplies and facility costs. The inventories—current line item on the balance sheet represents inventory forecasted to be sold or used in production in the next 12 months, as of the balance sheet date, and consists primarily of the cost of GoodWheat seed, grain, and flour, GLA oil, and hemp seed. The inventories—noncurrent line item on the balance sheet represents inventory expected to be used in production or sold beyond the next 12 months, as of the balance sheet date, and consists primarily of GoodWheat seed and grain, and GLA oil. Raw materials inventories consist primarily of the costs to produce GoodWheat seeds. Goods in process inventories consist of costs to produce GoodHemp seed, hemp seed production costs incurred by Archipelago, grower fees and related costs for soybeans to be transferred to Verdeca, and GoodWheat seed and grain. Finished goods inventories consist of GoodWheat products, GoodHemp seed and GLA oil that are available for sale. Property and Equipment Property and equipment acquisitions are recorded at cost. Provisions for depreciation are calculated using the straight-line method over the following average estimated useful lives of the assets: Years Laboratory equipment 5 Software and computer equipment 3 Machinery and equipment 2-20 Furniture and fixtures 7 Vehicles 5 Leasehold improvements 2-10 * * Leasehold improvements are depreciated over the shorter of the estimated life of the asset or the remaining life of the lease. Impairment of Long-Lived Assets The Company evaluates if events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and identifiable intangible assets may warrant revision or that the remaining balance of these assets may not be recoverable. In evaluating for recoverability, the Company estimates the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. In the event that the balance of any asset exceeds the future undiscounted cash flow estimate, impairment is recognized based on the excess of the carrying amounts of the asset above its estimated fair value. As of December 31, 2020 and 2019, there was no impairment of the Company’s long-lived assets. Fair Value of Financial Instruments Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. Assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities, are as follows: • Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date. • Level 2 inputs are observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 inputs are unobservable inputs for the asset or liability. The carrying values of the Company’s financial instruments, including cash equivalents, accounts receivable, and accounts payable approximated their fair values due to the short period of time to maturity or repayment. Concentration of Risk Cash and cash equivalents are maintained with several financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate its credit risks by spreading such risks across multiple counterparties and monitoring the risk profiles of these counterparties. Customer Concentration Significant customers are those that represent greater than 10% of the Company’s total revenues or gross accounts receivable balance at each respective balance sheet date. The Company had three customers that represented 57%, 21% and 12% of accounts receivable, and three customers that represented 47%, 17%, and 15% of accounts receivable, as of December 31, 2020 and 2019, respectively. The Company had one customer that represented 83% of total revenues, and two customers that represented 40% and 15% of total revenues, for the years ended December 31, 2020 and 2019, respectively. Stock-Based Compensation The Company recognizes compensation expense related to its employee stock purchase plan and the cost of stock-based compensation awards on a straight-line basis over the requisite service period, net of estimated forfeitures. Judgment is required in estimating the amount of stock-based awards that will be forfeited prior to vesting. Compensation expense could be revised in subsequent periods if actual forfeitures differ from those estimates. The Company has selected the Black-Scholes option-pricing model and various inputs to estimate the fair value of its stock-based awards. See Note 14 for additional information. Amounts recognized in the consolidated statements of operations and comprehensive loss were as follows (in thousands): Year Ended December 31, 2020 2019 (in thousands) Research and development $ 341 $ 321 Selling, general and administrative 1,701 1,966 Total stock-based compensation $ 2,042 $ 2,287 Income Taxes The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Net Loss per Share Basic net loss per share, which excludes dilution, is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock, such as stock options, convertible promissory notes, convertible preferred stock, redeemable convertible preferred stock and warrants, result in the issuance of common stock which share in the losses of the Company. Certain potential shares of common stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. Such potentially dilutive shares are excluded when the effect would be to reduce the loss per share. Due to net losses, there is no impact on earnings per share calculation in applying the two-class method since the participating securities have no legal requirement to share in any losses. Revenue Recognition The Company derives its revenues from product revenues, licensing agreements, royalties, contract research agreements, and government grants. Product Revenues Product revenues to date have consisted primarily of sales of SONOVA products, with initial GoodWheat seed sale revenues recognized in the fourth quarter of 2019 and initial GoodHemp seed sale revenues recognized in the fourth quarter of 2020. The Company recognizes revenue from product sales when control of the product is transferred to third-party distributors and manufacturers, collectively “our customers”, which generally occurs upon shipment. Revenues fluctuate depending on the timing of shipments of product to our customers. License Revenues License revenues to date consist of up-front, nonrefundable license fees, annual license fees, and subsequent milestone payments that the Company receives under the Company’s research and license agreements. The Company recognizes revenue generated from up-front, nonrefundable license fees upon execution of the agreement and recognizes annual license fees when it is probable that a material reversal will not occur. Milestone fees are variable consideration that is initially constrained and recognized only when it is probable that such amounts would not be reversed. The Company assesses when achievement of milestones is probable to determine the timing of revenue recognition for milestone fees Royalty Revenues Royalty revenues from the Company’s agreements with third parties related to GoodWheat products are recognized when the Company can reasonably determine the amounts earned. In most cases, this will be upon notification from the third-party licensee. Contract Research Revenues Contract research and government grant revenues consist of amounts earned from performing contracted research primarily related to breeding programs or the genetic engineering of plants for third parties. Contract research revenue is accounted for as a single performance obligation for which revenues are recognized over time using the input method (e.g., costs incurred to date relative to the total estimated costs at completion). Government Grant Revenues The Company receives payments from government entities in the form of government grants. Government grant revenue is accounted for as a single performance obligation for which revenues are recognized over time using the input method (e.g., costs incurred to date relative to the total estimated costs at completion). The Company’s obligation with respect to these agreements is to perform the research on a best-efforts basis. Unearned Revenue The Company defers revenue to the extent that cash received in conjunction with a license agreement, contract or grant exceeds the revenue recognized in accordance with Company policies. During the year ended December 31, 2020, the Company recognized revenue of $54,000 that was included in unearned revenue on the consolidated balance sheet as of December 31, 2019. Cost of Product Revenues Cost of product revenues relates to the sale of SONOVA and GoodWheat products and consists of in-licensing and royalty fees, any adjustments or write-downs to inventory, as well as the cost of raw materials, including inventory and third-party services costs related to procuring, processing, formulating, packaging, and shipping the Company’s products. Research and Development Expenses Research and development expenses consist of costs incurred in the discovery, development, and testing of the Company’s products and products in development incorporating the Company’s traits. These expenses consist primarily of employee salaries and benefits, fees paid to subcontracted research providers, fees associated with in-licensing technology, land leased for field trials, chemicals and supplies, and other external expenses. These costs are expensed as incurred. C hange in Fair Value of Contingent Consideration Change in the fair value of contingent consideration is comprised of the gain associated with the reduction of the contingent liability. See Note 15. C hange in the Estimated Fair Value of Common Stock Warrant Liabilities Change in the estimated fair value of common stock warrant liabilities is comprised of the fair value remeasurement of liability classified common stock warrants. See Note 13.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	12 Months Ended
Recent Accounting Pronouncements	Dec. 31, 2020
Accounting Changes And Error Corrections [Abstract]
Recent Accounting Pronouncements	Note 3. Recent Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02, Leases (Topic 842) In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Codification Improvements to Topic 326, Financial Instruments — Credit Losses (Topic 326) — Targeted Transition Relief, In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement The Company adopted ASU No. 2018-13 on January 1, 2020 and expanded its disclosures for significant unobservable inputs used to develop Level 3 fair value measurements. See Note 6. In June 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting Equity – Equity Based Payments to Non-Employees In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments are effective for all entities for fiscal years beginning after December 15, 2020. In April 2020, the FASB issued a staff question-and-answer (“Q&A”) document to respond to frequently asked questions about the accounting for lease concessions related to the effects of the COVID-19 pandemic. Under current GAAP, subsequent changes to lease payments that are not stipulated in the original lease contract are generally accounted for as lease modifications under Topic 842. The Q&A allows companies to make an accounting policy election to not evaluate lease concessions related to the effects of the COVID-19 pandemic as lease modifications. Entities that make this election then need to decide whether to apply the lease modification guidance in ASC 842 to the concession or account for the concession as if it were contemplated as part of the existing contract. The Company has not entered into any lease modifications that provide concessions related to the effects of the COVID-19 pandemic, and therefore has not evaluated its option to make this accounting policy election.

Inventory

Inventory	12 Months Ended
Inventory	Dec. 31, 2020
Inventory Disclosure [Abstract]
Inventory	Note 4. Inventory Inventory costs are tracked on a lot-identified basis and are included as cost of product revenues when sold. Inventories are stated at the lower of cost or net realizable value. The Company makes adjustments to inventory when conditions indicate that the net realizable value may be less than cost due to physical deterioration, obsolescence, changes in price levels, or other factors. Additional adjustments to inventory are made for excess and slow-moving inventory on hand that is not expected to be sold within a reasonable timeframe to reduce the carrying amount to its estimated net realizable value. The write-downs to inventory are included in cost of product revenues and are based upon estimates about future demand from the Company’s customers and distributors and market conditions. Therefore, if there are significant changes in demand and market conditions, substantial future write-downs of inventory may be required, which would materially increase our expenses in the period the write down is taken and materially affect our operating results. The Company recorded write-downs of wheat inventories, hemp seed inventories, and prepaid production costs of $4.3 million for the year ended December 31, 2020. The Company recorded $304,000 of inventory write-downs for the year ended December 31, 2019. Inventories, net consist of the following (in thousands): December 31, 2020 December 31, 2019 Raw materials $ 966 $ 67 Goods in process 1,921 188 Finished goods 4,410 1,903 Inventories $ 7,297 $ 2,158

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
Property and Equipment, Net	Dec. 31, 2020
Property Plant And Equipment [Abstract]
Property and Equipment, Net	Note 5. Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): As of December 31, 2020 2019 Laboratory equipment $ 2,951 $ 2,443 Software and computer equipment 591 502 Machinery and equipment 2,046 989 Furniture and fixtures 181 90 Vehicles 428 395 Leasehold improvements 2,229 2,023 Property and equipment, gross 8,426 6,442 Less accumulated depreciation and amortization (4,887 ) (4,643 ) Property and equipment, net $ 3,539 $ 1,799 Depreciation expense was $632,000 and $194,000 for the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020 and 2019, respectively, there was $239,000 and $1,014,000 of construction in progress included in property and equipment that had not been placed into service and was not subject to depreciation.

Investments and Fair Value Inst

Investments and Fair Value Instruments	12 Months Ended
Investments and Fair Value Instruments	Dec. 31, 2020
Investments And Fair Value Instruments [Abstract]
Investments and Fair Value Instruments	Note 6. Investments and Fair Value Instruments Investments The Company classified its investments in corporate securities of BIOX as short-term investments. The investments are carried at fair value, based on quoted market prices or other readily available market information. Unrealized and realized gains and losses are recognized as Other income in the consolidated statements of operations and comprehensive loss. The following tables summarize the amortized cost and fair value of the investment securities portfolio at December 31, 2020 and December 31, 2019, and the corresponding amounts of unrealized gains and losses recognized in other income, net, in the consolidated statements of operations and comprehensive loss: (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value December 31, 2020 Cash equivalents: Money market funds $ 12,082 $ — $ — $ 12,082 Short-term investments: Corporate securities 10,969 656 — 11,625 Total Assets at Fair Value $ 23,051 $ 656 $ — $ 23,707 (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value December 31, 2019 Cash equivalents: Money market funds $ 6,864 $ — $ — $ 6,864 Commercial paper 900 — — 900 Short-term investments: Corporate securities 3,300 — — 3,300 Treasury bills 1,495 1 — 1,496 Commercial paper 12,119 — — 12,119 Total Assets at Fair Value $ 24,678 $ 1 $ — $ 24,679 The Company did not have any investment categories that were in a continuous unrealized loss position for more than twelve months as of December 31, 2020. Fair Value Measurement The fair value of the investment securities at December 31, 2020 were as follows: Fair Value Measurements at December 31, 2020 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 12,082 $ — $ — $ 12,082 Short-term investments: Corporate securities 11,625 — — 11,625 Total Assets at Fair Value $ 23,707 $ — $ — $ 23,707 The fair value of the investment securities at December 31, 2019 were as follows: Fair Value Measurements at December 31, 2019 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 6,864 $ — $ — $ 6,864 Commercial paper — 900 — 900 Short-term investments: Corporate securities — 3,300 — 3,300 Treasury bills 1,496 — — 1,496 Commercial paper — 12,119 — 12,119 Total Assets at Fair Value $ 8,360 $ 16,319 $ — $ 24,679 The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2020 or 2019. The Company’s financial instruments consist primarily of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, and notes payable. For accounts receivable, accounts payable, accrued liabilities, and notes payable the carrying amounts of these financial instruments as of December 31, 2020 and 2019 were considered representative of their fair values due to their short term to maturity or repayment. Cash equivalents are carried at cost, which approximates their fair value. The Company’s Level 3 liabilities consist of a contingent liability resulting from the Anawah acquisition, as described in Note 15, a contingent liability resulting from the Industrial Seed Innovations acquisition, as described in Note 7, and liabilities related to the March 2018, the June 2019 and the September 2019 Offerings described in Note 13. The contingent liability was measured and recorded on a recurring basis as of December 31, 2020 and 2019 using unobservable inputs, namely the Company’s ability and intent to pursue certain specific products developed using technology acquired in the purchase T he warrant liabilities were measured and recorded on a recurring basis September 2019 Warrants June 2019 Warrants June 2018 Warrants March 2018 Warrants December 31, 2020 December 31, 2019 December 31, 2020 December 31, 2019 December 31, 2020 December 31, 2019 December 31, 2020 December 31, 2019 Expected term (in years) 4.20 5.20 3.96 4.96 — 3.96 2.22 3.22 Expected volatility 135.0 % 120.0 % 135.0 % 120.0 % — 123.0 % 130.0 % 125.0 % Risk-free interest rate 0.3 % 1.7 % 0.3 % 1.7 % — 1.7 % 0.1 % 1.6 % Expected dividend yield 0 % 0 % 0 % 0 % — 0 % 0 % 0 % The significant unobservable input used in the fair value measurement of the Company’s Level 3 warrant liabilities is volatility. A significant increase (decrease) in volatility could result in a significantly higher (lower) fair value measurement. The following table sets forth the establishment of the Company’s Level 3 liabilities, as well as a summary of the changes in the fair value and other adjustments (in thousands): (Level 3) (Dollars in thousands) Common Stock Warrant Liability - March 2018 Purchase Agreement Common Stock Warrant Liability - June 2018 Offering Common Stock Warrant Liability - June 2019 Offering Common Stock Warrant Liability - September 2019 Offering Contingent Liabilities Total Balance as of December 31, 2018 $ 2,354 $ 2,729 $ — $ — $ 3,000 $ 8,083 Common stock and warrants issued in conjunction with June 2019 Offering — — 4,198 — — $ 4,198 Common stock and warrants issued in conjunction with September 2019 Offering — — — 3,428 — $ 3,428 Change in fair value and other adjustments 2,225 2,715 4,811 (508 ) (1,000 ) $ 8,243 Exercise of warrants - - (7,016 ) - - $ (7,016 ) Balance as of December 31, 2019 $ 4,579 $ 5,444 $ 1,993 $ 2,920 $ 2,000 $ 16,936 Change in fair value and other adjustments (2,277 ) (1,426 ) (1,161 ) (1,706 ) — $ (6,570 ) Exercise of warrants (1,641 ) (4,018 ) — — — $ (5,659 ) ISI acquisition contingent consideration — — — — 280 $ 280 Balance as of December 31, 2020 $ 662 $ — $ 832 $ 1,214 $ 2,280 $ 4,987

Industrial Seed Innovations Acq

Industrial Seed Innovations Acquisition	12 Months Ended
Industrial Seed Innovations Acquisition	Dec. 31, 2020
Business Combinations [Abstract]
Industrial Seed Innovations Acquisition	Note 7. Industrial Seed Innovations Acquisition On August 21, 2020, the Company acquired by merger Industrial Seed Innovations (ISI), an Oregon-based industrial hemp breeding and seed company. As a result of the acquisition, the Company acquired ISI’s commercial and genetic assets, including seed varieties, germplasm library and intellectual property. ISI’s Rogue and Umpqua seed varieties are now part of Arcadia’s portfolio, alongside the Company’s GoodHemp line of genetically superior hemp seeds, transplants, and extracts. The acquisition has significantly broadened and accelerated commercialization of Arcadia’s hemp-related breeding platform, as well as established a breeding research and development facility in the Pacific Northwest, a key production area in the hemp industry. The purchase price consideration for the acquisition totaled an estimated $1,212,000, of which $500,000 in cash and $432,000 in the form of 132,626 shares of the Company’s common stock, was paid during the month of August 2020. The remaining amount of $280,000 will be recognized in two annual installments, each of up to 132,626 shares of the Company’s common stock, subject to the achievement of revenue milestones in 2021 and 2022, and is recorded as a contingent liability in the consolidated balance sheets as of December 31, 2020. The cash consideration paid for the acquisition was funded by cash on hand. For the year ended December 31, 2020, no revenues from ISI were recorded, and expenses were immaterial. The pro forma impact of the acquisition to the historical financial results was determined not to be significant. Acquisition costs are not included as components of consideration transferred and instead are accounted for as expenses in the period in which the costs are incurred. The Company incurred costs related to the ISI acquisition of approximately $67,000 included in selling, general and administrative expenses in the Company's consolidated statements of operations and comprehensive loss. The following table presents the allocation of the purchase price of ISI assets acquired, based on their relative fair values, which have been assessed during the year ended December 31, 2020. Intangible assets will be amortized based on their useful life of five years, and their balance as of December 31, 2020 was $370,000. A deferred tax liability arising from the difference between book purchase price allocation and tax basis has been assessed in the amount of $107,000. Deferred tax liabilities are required to be recorded in purchase accounting independently of whether the acquiror has a valuation allowance on its own net deferred tax assets. As a result, the combined entity now has additional deferred tax liabilities available to reduce the amount of valuation allowance necessary. Future reversals of existing taxable temporary differences are an objective source of future taxable income. Accordingly, the purchase accounting deferred tax liabilities enabled the realization of a portion of the existing deferred tax assets, thus allowing for a reduction in the valuation allowance. The reduction in the valuation allowance is not accounted for as part of the purchase accounting but is recognized in the consolidated statements of operations and comprehensive loss as a discrete tax benefit in the income tax provision. Purchase Price Allocation Inventory $ 511 Intangible assets, net 400 Goodwill 408 Deferred tax liability (107 ) Total consideration allocated $ 1,212 The former shareholders of ISI remain responsible for ISI’s pre-acquisition liabilities. Pursuant to the definitive acquisition agreement, the Company entered into a lease agreement with ISI for the use of land, equipment, greenhouses and buildings. The lease was effective upon the execution of the definitive acquisition agreement and has a term of 3 years with the option to renew for three additional 3-year terms.

Consolidated Joint Venture

Consolidated Joint Venture	12 Months Ended
Consolidated Joint Venture	Dec. 31, 2020
Equity Method Investments And Joint Ventures [Abstract]
Consolidated Joint Venture	Note 8. On August 9, 2019, the Company and Legacy Ventures Hawaii, LLC, a Nevada limited liability company (“Legacy”), formed Archipelago Ventures Hawaii, LLC, a Delaware limited liability company and entered into a Limited Liability Company Operating Agreement (the “Operating Agreement”). The Company and Legacy formed Archipelago to develop, extract and commercialize hemp-derived products from industrial hemp grown in Hawaii. Pursuant to the Operating Agreement, a joint operating committee consisting of two individuals appointed by the Company and two individuals appointed by Legacy will manage Archipelago. As of December 31, 2020, the Company and Legacy hold 50.75% and 49.25% interests in Archipelago, respectively, and have made capital contributions to Archipelago of $2,336,000 and $2,267,000, respectively, as determined by the joint operating committee. The Operating Agreement includes indemnification rights, non-competition obligations, and certain rights and obligations in connection with the transfer of membership interests, including rights of first refusal. The Company consolidates Archipelago in the consolidated financial statements after eliminating intercompany transactions. Net loss attributable to non-controlling interest of $1,371,000 and $68,000 is recorded as an adjustment to net loss to arrive at net loss attributable to common stockholders for the years ended December 31, 2020 and 2019, respectively. Legacy’s equity interests are presented as non-controlling interests on the consolidated balance sheets. Refer to Note 2 for basis of presentation.

Verdeca-BIOX Transactions

Verdeca-BIOX Transactions	12 Months Ended
Verdeca-BIOX Transactions	Dec. 31, 2020
Equity Method Investments And Joint Ventures [Abstract]
Verdeca-BIOX Transactions	Note 9. Verdeca-BIOX Transactions In February 2012, the Company formed Verdeca, which was equally owned with Bioceres. Verdeca was formed to develop and deregulate soybean varieties using both partners’ agricultural technologies. On November 12, 2020, the Company entered into a Master Transaction Agreement with Bioceres Crop Solutions Corp. (“BIOX”) pursuant to which (i) the Company sold all of its memberships interests it owned in Verdeca to BIOX, and (ii) the Company and BIOX entered into a license agreement for certain intellectual property rights, including rights to the Company’s HB4 soybean trait and its GoodWheat portfolio of specialty wheat products in South and Central America. Prior to the transaction, Verdeca was equally owned by the Company and a wholly-owned subsidiary of BIOX. In consideration for the sale of the membership interests in Verdeca and entering into the license agreement, on November 12, 2020, BIOX paid the Company $5,000,000 in cash and issued the Company 1,875,000 shares of BIOX common stock. BIOX will also pay the Company an additional (i) $1,000,000 payable in five equal monthly payments beginning on December 12, 2020 for transaction expenses and fees and (ii) $2,000,000 payable in four equal quarterly payments with the first payment commencing within thirty days of either BIOX reaching commercial plantings of at least 200,000 hectares of Haab 4 soybeans (“HB4”) or if China approves the HB4 soybean trait for “food and feed”. In addition to the above payments, BIOX will also pay the Company quarterly royalty payments equal to six percent (6%) of the net revenues BIOX or its affiliates receive from HB4 soybean sales and twenty five percent (25%) of the net revenues BIOX or its affiliates receive from sales of licensed wheat products; provided that royalty payments for HB4 soybeans shall not exceed $10,000,000. The total amount of fixed consideration agreed upon as of the date of the transaction was $16,968,750. The fixed consideration was allocated based on estimates of the stand-alone selling prices. A fixed consideration in the amount of $10,288,000, including $6,650,000 of corporate securities received, has been allocated to the sale of the membership interest in Verdeca and resulted in a gain of $8,814,000 recorded on the consolidated statements of operations and comprehensive loss for the year ended December 31, 2020. Inventory with a carrying value of $1,474,000 was derecognized in connection with the sale of the membership interest in Verdeca. A fixed consideration in the amount of $6,680,000, including $4,318,000 of corporate securities received, has been allocated to the sale of intellectual property rights and has been recorded as license revenues on the consolidated statements of operations and comprehensive loss for the year ended December 31, 2020. As of December 31, 2020, the Company has $800,000 recorded within accounts receivable on its consolidated balance sheets related to this transaction. Any future proceeds from the agreement will be allocated in the same proportion. The Company agreed not to sell or transfer any shares of BIOX common stock it received in this transaction for a period of 180 days without the prior written consent of BIOX, subject to certain exceptions allowing the Company to pledge shares to a lender as collateral.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	12 Months Ended
Accounts Payable and Accrued Expenses	Dec. 31, 2020
Payables And Accruals [Abstract]
Accounts Payable and Accrued Expenses	Note 10. Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consisted of the following (in thousands): As of December 31, 2020 2019 Accounts payable - trade $ 726 $ 492 Payroll and benefits 1,489 1,290 Inventory 965 1,143 Research and development 45 629 Royalty fees due to unrelated parties 276 226 Consulting 153 397 Rent and utilities 78 23 Audit and tax fees 57 113 Legal 152 138 Other 164 234 Total accounts payable and accrued expenses $ 4,105 $ 4,685

Collaborative Arrangements

Collaborative Arrangements	12 Months Ended
Collaborative Arrangements	Dec. 31, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Collaborative Arrangements	Note 11. Collaborative Arrangements In August 2017, the Company entered into a collaborative arrangement for the research, development and commercialization of an improved wheat quality trait in North America. This collaborative arrangement is a contractual agreement with Corteva Agriscience (“Corteva”) involves a joint operating activity where both Arcadia and Corteva are active participants in the activities of the collaboration. Arcadia and Corteva participate in the research and development, and Arcadia has the primary responsibility for the intellectual property strategy while Corteva will generally lead the marketing and commercialization efforts. Both parties are exposed to significant risks and rewards of the collaboration and the agreement includes both cost sharing and profit sharing. The activities are performed with no guarantee of either technological or commercial success. The Company accounts for research and development (“R&D”) costs in accordance ASC 730, Research and Development

Equity Financing

Equity Financing	12 Months Ended
Equity Financing	Dec. 31, 2020
Equity [Abstract]
Equity Financing	Note 12. Equity Financing Private Placements In March 2018, the Company issued in a private placement offering (the “March 2018 Private Placement”) pursuant to a securities purchase agreement (“March 2018 Purchase Agreement”) (i) 300,752 shares of its common stock and (ii) warrants to purchase up to 300,752 shares of common stock at an initial exercise price equal to $45.75 (the “March 2018 Warrants”) and raised total gross proceeds of $10.0 million. The March 2018 Warrants are exercisable at any time at the option of the holder and expire five years from the date of issuance. In connection with the March 2018 Private Placement, the Company granted to a placement agent warrants to purchase a total of 15,038 shares of Common Stock (the “March 2018 Placement Agent Warrants”) that have an exercise price per share equal to $41.5625 and a term of five years from the date of issuance. The number of shares of common stock and the number and exercise price of the March 2018 Warrants issued in the March 2018 Private Placement were subject to adjustments as provided in the March 2018 Purchase Agreement. Following the adjustments as provided in the March 2018 Purchase Agreement, the number of shares issued to the purchasers was 1,201,634, the total number of shares issuable upon exercise of the March 2018 Warrants was 1,282,832 and the per share exercise price of the March 2018 Warrants was $10.7258. Registered Direct Offerings On May 11, 2018, the Company filed a shelf Registration Statement on Form S-3 with the SEC which was declared effective on June 8, 2018 (“Shelf Registration Statement”). This shelf registration process allows the Company to sell any combination of common stock, preferred stock, warrants and units consisting of such securities in one or more offerings from time to time having aggregate offering prices of up to $50 million. In June 2018, the Company entered into a securities purchase agreement (the “June 2018 Purchase Agreement”) pursuant to which it sold (i) 1,392,345 registered shares of its common stock pursuant to the Shelf Registration Statement and (ii) unregistered warrants to purchase 1,392,345 shares of its common stock (the “June 2018 Warrants”) in a private placement June 2018 Warrants 5.5 years In June 2019, the Company entered into a securities purchase agreement (the “June 2019 Purchase Agreement”) pursuant to which it sold (i) 1,489,575 registered shares of its common stock pursuant to the Shelf Registration Statement and (ii) unregistered warrants to purchase 1,489,575 shares of its common stock (the “June 2019 Warrants”) in a private placement June 2019 Warrants 5.5 years In September 2019, the Company entered into a securities purchase agreement (the “September 2019 Purchase Agreement”) pursuant to which it sold (i) 1,318,828 registered shares of its common stock pursuant to the Shelf Registration Statement and (ii) unregistered warrants to purchase 659,414 shares of its common stock (the “September 2019 Warrants”) in a private placement September 2019 Warrants 5.5 years In December 2020, the Company entered into a securities purchase agreement (the “December 2020 Purchase Agreement”) pursuant to which it sold (i) 2,618,658 registered shares of its common stock pursuant to the Shelf Registration Statement and (ii) unregistered warrants to purchase 2,618,658 shares of its common stock (the “December 2020 Warrants”) in a private placement December 2020 Warrants 5.5 years

Warrants

Warrants	12 Months Ended
Warrants	Dec. 31, 2020
Warrants And Rights Note Disclosure [Abstract]
Warrants	Note 13. Warrants Common Stock Warrant transactions In May 2020, several existing accredited investors exercised the June 2018 Warrants (the “May 2020 Warrant Exercise Transaction”) to purchase up to an aggregate of 1,392,345 shares of the Company’s common stock at a reduced exercise price of $4.90 per share for gross proceeds of $6.8 million. As consideration for the exercise of the June 2018 Warrants, the Company issued new unregistered warrants to purchase up to 1,392,345 shares of common stock (the “May 2020 Warrants”) at an exercise price of $4.775 per share with an exercise period of five years from the date of issuance. The May 2020 Warrants were valued at $4.4 million, which was calculated using the Black-Scholes Model with the following assumptions: volatility of 128 percent, stock price of $3.81, and risk-free rate of 0.38%. In connection with the May 2020 Warrant Exercise Transaction, the Company granted to a placement agent warrants to purchase a total of 69,617 shares of common stock (the “May 2020 Placement Agent Warrants”) that have an exercise price per share equal to $6.125 and a term of five years. The value of the May 2020 Placement Agent Warrants was determined to be $215,000 using the Black-Scholes Model. The Company recognized a gain on extinguishment of warrant liability in the amount of $47,000 associated with this transaction, during the quarter ended June 30, 2020. In July 2020, an existing accredited investor exercised its March 2018 Warrants (the “July 2020 Warrant Exercise Transaction”) to purchase up to an aggregate of 641,416 shares of the Company’s common stock at a reduced exercise price of $3.975 per share for gross proceeds of $2.6 million. As consideration for the exercise of these March 2018 Warrants, the Company issued new unregistered warrants to purchase up to 641,416 shares of common stock (the “July 2020 Warrants”) at an exercise price of $3.85 per share with an exercise period of 5.5 years from the date of issuance. The July 2020 Warrants were valued at $2.1 million, which was calculated using the Black-Scholes Model with the following assumptions: volatility of 126 percent, stock price of $3.73, and risk-free rate of 0.35%. In connection with the July 2020 Warrant Exercise Transaction, the Company granted to a placement agent warrants to purchase a total of 32,071 shares of common stock (the “July 2020 Placement Agent Warrants”) that have an exercise price per share equal to $4.969 and a term of 5.5 years. The value of the July 2020 Placement Agent Warrants was determined to be $101,000 using the Black-Scholes Model. The Company recognized a loss on extinguishment of warrant liability in the amount of $682,000 associated with this transaction, during the quarter ended September 30, 2020. Equity Classified Common Stock Warrants In connection with professional services agreements with non-affiliated third parties, during the years ended December 31, 2020 and 2019, the Company issued service and performance warrants (“Service and Performance Warrants”). As of December 31, 2020, the Company issued the following warrants to purchase shares of its common stock. These warrants are exercisable any time at the option of the holder until their expiration date. Issuance Date Term Exercise Price Per Share Warrants Exercised during the Year Ended December 31, 2019 Warrants Outstanding at December 31, 2019 Warrants Exercised during the Year Ended December 31, 2020 Warrants Outstanding at December 31, 2020 December 2020 Warrants December 2020 5.5 years $ 3.00 — — — 2,618,658 December 2020 Placement Agent Warrants December 2020 5 years $ 3.82 — — — 130,933 July 2020 Warrants July 2020 5.5 years $ 3.85 — — — 641,416 July 2020 Placement Agent Warrants July 2020 5.5 years $ 4.97 — — — 32,071 May 2020 Warrants May 2020 5 years $ 4.78 — — — 1,392,345 May 2020 Placement Agent Warrants May 2020 5 years $ 6.13 — — — 69,617 March 2020 Service and Performance Warrants March 2020 3 years $ 2.50 — — — 18,350 February 12, 2020 Service and Performance Warrants February 2020 2 years $ 4.71 — — — 150,000 February 3, 2020 Service and Performance Warrants February 2020 2 years $ 4.91 — — — 10,000 September 2019 Placement Agent Warrants September 2019 5 years $ 9.48 — 65,942 — 65,942 August 2019 Service and Performance Warrants August 2019 2 years $ 1.92 — 20,000 — 20,000 July 2019 Service and Performance Warrants July 2019 2 years $ 2.19 — 10,000 — 10,000 June 2019 Placement Agent Warrants June 2019 5 years $ 6.29 — 74,479 — 74,479 April 2019 Service and Performance Warrants April 2019 5 years $ 6.18 — 145,154 — 145,154 June 2018 Placement Agent Warrants June 2018 5 years $ 12.57 — 69,617 — 69,617 March 2018 Placement Agent Warrants March 2018 5 years $ 41.56 — 15,038 — 15,038 Total — 400,230 — 5,463,620 Liability Classified Common Stock Warrants Certain warrants contain a contingent cash payment feature and therefore were accounted for as a liability at the date of issuance and are adjusted to fair value at each balance sheet date. The change in fair value of the warrant liability is recorded as change in fair value of common stock warrant liabilities in the consolidated statements of operations and comprehensive loss. The key terms and activity of the liability classified common stock warrants are summarized as follows: Issuance Date Term Exercise Price Per Share Warrants Exercised during the Year Ended December 31, 2019 Warrants Outstanding at December 31, 2019 Warrants Exercised during the Year Ended December 31, 2020 Warrants Outstanding at December 31, 2020 September 2019 Warrants September 2019 5.5 years $ 7.52 — 659,414 — 659,414 June 2019 Warrants June 2019 5.5 years $ 5.00 1,053,745 435,830 — 435,830 June 2018 Warrants June 2018 5.5 years $ 9.94 — 1,392,345 1,392,345 — March 2018 Warrants March 2018 5 years $ 10.73 — 1,282,832 641,416 641,416 Total 1,053,745 3,770,421 2,033,761 1,736,660 See Note 6 for the Black-Scholes option-pricing model and weighted-average assumptions used to estimate the fair value of the warrant liabilities.

Stock-Based Compensation and Em

Stock-Based Compensation and Employee Stock Purchase Program	12 Months Ended
	Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation and Employee Stock Purchase Program	Note 14. Stock-Based Compensation and Employee Stock Purchase Program Stock Incentive Plans The Company has two equity incentive plans: the 2006 Stock Plan (“2006 Plan”) and the 2015 Omnibus Equity Incentive Plan (“2015 Plan”). In 2006, the Company adopted the 2006 Plan, which provided for the granting of stock options to executives, employees, and other service providers under terms and provisions established by the Board of Directors. The Company granted non-statutory stock options (“NSOs”) under the 2006 Plan until May 2015, when it was terminated as to future awards, although it continues to govern the terms of options that remain outstanding and were issued under the 2006 Plan. The 2015 Plan became effective upon the Company’s IPO in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 154,387 shares of common stock reserved for future issuance, which included 10,637 that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan. The 2015 Plan provides for the grant of incentive stock options (“ISOs”), NSOs, restricted stock awards, stock units, stock appreciation rights, and other forms of equity compensation, all of which may be granted to employees, officers, non-employee directors, and consultants. The ISOs and NSOs will be granted at a price per share not less than the fair value at the date of grant. Options granted generally vest over a four-year period; however, the options granted in the third quarter of 2018 vest over two-year period, vesting monthly on a pro-rated basis. Options granted, once vested, are generally exercisable for up to 10 years, after grant. In June 2019, the shareholders approved an amendment to the Company’s 2015 Plan for a one-time increase to the number of shares of common stock that may be issued under the 2015 Plan by 120,000 shares. As of December 31, 2020, a total of 1,047,243 shares of common stock were reserved for issuance under the 2015 Plan, of which 157,484 shares of common stock are available for future grant. As of December 31, 2020, a total of 19,172 and 870,587 options are outstanding under the 2006 and 2015 Plans, respectively. As of December 31, 2019, a total of 45,229 and 616,472 options are outstanding under the 2006 and 2015 Plans, respectively. The following is a summary of stock option information and weighted average exercise prices under the Company’s stock incentive plans (in thousands, except share data and price per share): Shares Subject to Outstanding Options Weighted- Average Exercise Price Per Share Aggregate Intrinsic Value Outstanding — Balance at December 31, 2018 530,044 $ 35.53 $ — Options granted 208,571 5.13 Options exercised (546 ) 4.63 Options forfeited (30,132 ) 33.95 Options expired (46,236 ) 98.69 Outstanding — Balance at December 31, 2019 661,701 21.60 $ 305 Options granted 502,494 4.28 Options exercised — — Options forfeited (174,508 ) 5.91 Options expired (99,928 ) 25.56 Outstanding — Balance at December 31, 2020 889,759 14.46 $ 240 Vested and expected to vest — December 31, 2020 841,991 15.03 $ 240 Exercisable —December 31, 2020 502,973 $ 22.20 $ — Aggregate intrinsic value represents the difference between the exercise price of the options and the estimated fair value of the Company’s common stock determined by our Board of Directors for each of the respective periods. The intrinsic value of options exercised was $0 for both years ended December 31, 2020 and 2019. As On August 22, 2019, Rajendra Ketkar provided notice to the Company of his retirement as Arcadia’s president, chief executive officer and director, effective as of September 1, 2019. On August 23, 2019, Arcadia and Mr. Ketkar entered into a Separation and Release Agreement (the “Separation Agreement”) which provides that the vesting of certain options previously issued to Mr. Ketkar will be accelerated pursuant to the terms of the Separation Agreement. In addition, the Separation Agreement extends the post-termination exercise period of the accelerated options from 90 days to up to two years. The stock compensation expense related to the modification of Mr. Ketkar’s stock options was $438,000 and recognized in selling, general and administrative expenses during the year ended December 31, 2019. In determining the fair value of the stock-based awards, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine. Expected T The expected term is the estimated period of time outstanding for stock options granted and was estimated based on a simplified method allowed by the SEC due to insufficient historical data, and defines the term as the average of the contractual term of the options and the weighted-average vesting period for all open employee awards. Expected V Since the Company was privately held and does not have a long trading history for its common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded biotechnology companies over a period equal to the expected term of the stock option grants. When selecting comparable publicly traded biotechnology companies on which it has based its expected stock price volatility, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected life of the stock-based awards. The historical volatility data was computed using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. Ris k F The risk-free interest rate is based on the interest rate of U.S. Treasuries of comparable maturities on the date the options were granted. Expected The expected dividend yield is based on the Company’s expectation of future dividend payouts to common stockholders. The Year Ended December 31, Assumptions 2020 2019 Expected term (years) 6.48 7.04 Expected volatility 134% 99% Risk-free interest rate 1.01% 2.01% Expected dividend yield — — The Employee Stock Purchase Plan The Company’s 2015 Employee Stock Purchase Plan (“ESPP”) became effective on May 14, 2015. The ESPP allows eligible employees to purchase shares of the Company’s common stock at a discount of up to 15% of their eligible compensation through payroll deductions, subject to any plan limitations. After the first offering period, which began on May 14, 2015 and ended on February 1, 2016, the ESPP provides for six-month offering periods, and at the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last day of the offering period. As of December 31, 2020, the number of shares of common stock reserved for future issuance under the ESPP is 105,036. The ESPP provides for automatic annual increases in the shares available for purchase beginning on January 1, 2016. As of December 31, 2020, 35,056 shares had been issued under the ESPP. The Company recorded $47,000 and $16,000 of ESPP related compensation expense for the years ended December 31, 2020 and 2019, respectively.

Commitment and Contingencies

Commitment and Contingencies	12 Months Ended
Commitment and Contingencies	Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 15. Commitments and Contingencies Leases The Company leases office and laboratory space, greenhouse space, grain storage bins, warehouse space, farmland, and equipment under operating lease agreements having initial lease terms ranging from one to five years, including certain renewal options available to the Company at market rates. The Company also leases land for field trials on a short-term basis. See Note 16. Legal Matters From time to time, in the ordinary course of business, the Company may become involved in certain legal proceedings. The Company currently is not a party to any material litigation or other material legal proceedings. Contingent Liability Related to the Anawah Acquisition On June 15, 2005, the Company completed its agreement and plan of merger and reorganization with Anawah, Inc. (“Anawah”), to purchase the Anawah’s food and agricultural research company through a non-cash stock purchase. Pursuant to the merger with Anawah, and in accordance with the ASC 805 - Business Combinations, the Company incurred a contingent liability not to exceed $5.0 million. This liability represents amounts to be paid to Anawah’s previous stockholders for cash collected on revenue recognized by the Company upon commercial sale of certain specific products developed using technology acquired in the purchase. As of December 31, 2010, the Company ceased activities relating to three of the six Anawah product programs thus, the contingent liability was reduced to $3.0 million. During the third quarter of 2016, one of the programs previously accrued for was abandoned and another program previously abandoned was reactivated. During the fourth quarter of 2019, the Company determined that one of the technologies was no longer active and decided to abandon the previously accrued program. As a result, the Company recognized a gain of $1.0 million in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2019. As of December 31, 2020, the Company continues to pursue a total of two development programs using this technology and believes that the contingent liability is probable. As a result, $2.0 million remains on the consolidated balance sheet as an other noncurrent liability. Contingent Liability Related to the ISI Acquisition On August 21, 2020, the Company acquired by merger Industrial Seed Innovations (ISI). A portion of the purchase price consideration for the acquisition in the amount of $280,000 will be recognized in two annual installments, each of up to 132,626 shares of the Company’s common stock, subject to the achievement of revenue milestones in 2021 and 2022. The contingent consideration of $280,000 was measured and recorded at fair value as of the acquisition date using a third-party valuation specialist. As of December 31, 2020, the full amount of the contingent consideration is included in other noncurrent liabilities as no installments will become due within 12 months from the consolidated balance sheets date. As of December 31, 2020, no material changes in its fair value have been observed since the acquisition date in August 2020. Contracts The Company has entered into contract research agreements with unrelated parties that require the Company to pay certain funding commitments. The initial terms of these agreements range from one to three years in duration and in certain cases are cancelable. The Company licenses certain technologies via executed agreements (“In-Licensing Agreements”) that are used to develop and advance the Company’s own technologies. The Company has entered into various In-Licensing Agreements with related and unrelated parties that require the Company to pay certain license fees, royalties, and/or milestone fees. In addition, certain royalty payments ranging from 2% to 15% of net revenue amounts as defined in the In-Licensing Agreements are or will be due. Royalties due to both related and unrelated parties on license revenue accrued as of December 31, 2020 and 2019 were $356,000 and $266,000, respectively. Accrued royalties are included within accounts payable and accrued expenses on the consolidated balance sheets, and within research and development on the consolidated statements of operations and comprehensive loss. Milestone payments are contingent upon the successful development or implementation of various technologies. Payments for milestones yet to be achieved totaled $2.0 million for both the years ended December 31, 2020 and 2019, respectively. The timing of the payments is not determinable at this time pending research and development currently in progress; however, no payments were made during the years ended December 31, 2020 and 2019. The Company could be adversely affected by certain actions by the government as it relates to government contract revenue received in prior years. Government agencies, such as the Defense Contract Audit Agency routinely audit and investigate government contractors. These agencies review a contractor’s performance under its agreements; cost structure; and compliance with applicable laws, regulations and standards. The agencies also review the adequacy of, and a contractor’s compliance with, its internal control systems and policies, including the contractor’s purchasing, property, estimating, compensation and management information systems. While the Company’s management anticipates no adverse result from an audit, should any costs be found to be improperly allocated to a government agreement, such costs will not be reimbursed, or if already reimbursed, may need to be refunded. If an audit uncovers improper or illegal activities, civil and criminal penalties and administrative sanctions, including termination of contracts, forfeiture of profits, suspension of payments or fines, and suspension or prohibition from doing business with the government could occur. In addition, serious reputational harm or significant adverse financial effects could occur if allegations of impropriety were made against the Company. There currently are routine audits in process relating to government grant revenues.

Leases

Leases	12 Months Ended
Leases	Dec. 31, 2020
Lessee Disclosure [Abstract]
Leases	Note 16. Leases Operating Leases As of December 31, 2020, the Company leases office space in Davis, CA, Phoenix, AZ, and Molokai, HI, as well as additional buildings, land and equipment. Leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these short-term leases on a straight-line basis. The Company subleases a portion of the Davis office lease to third parties. During the year ended December 31, 2020, the Company entered into four lease amendments, including one that provides for additional office space in Davis, CA, and extends the term through April 2025, with one option to renew for an additional five-year term. The Company expects to exercise its options to renew, and in accordance with ASC 842, accounted for the amendment and expected renewal as a lease modification and remeasured the operating lease liability, resulting in an additional $3.8 million operating lease liability and right of use asset. The Company also entered into a lease amendment for additional parcels of land in Molokai, HI, modified the Molokai office space lease to extend the term by 12 months, and entered into new lease agreements for office equipment, collectively resulting in an additional $0.1 million of operating lease liabilities and right of use assets. The Company also entered into a lease amendment for the land and greenhouses in Woodland, CA, extending the term by four years collectively, and resulting in an additional $0.3 million of operating lease liabilities and right of use assets. In connection with the ISI Acquisition, the Company entered into a new lease for the premises and equipment in Oregon with a three-year term, resulting in an additional $0.2 million of operating lease liabilities and right of use assets. There are no finance leases or material leases that have not yet commenced as of December 31, 2020. Some leases (the Davis office, warehouse, greenhouses and a copy machine) include one or more options to renew, with renewal terms that can extend the lease term from one to six years. The exercise of lease renewal options is at the Company’s sole discretion. The Company’s lease agreements do not contain any material variable lease payments, material residual value guarantees or material restrictive covenants. Leases consisted of the following (in thousands): Leases Classification December 31, 2020 December 31, 2019 Assets Operating lease assets Right of use asset $ 5,826 $ 1,963 Total leased assets $ 5,826 $ 1,963 Liabilities Current - Operating Operating lease liability - current $ 717 $ 611 Noncurrent - Operating Operating lease liability - noncurrent 5,389 1,497 Total leased liabilities $ 6,106 $ 2,108 Lease Cost Classification For the Year Ended December 31, 2020 For the Year Ended December 31, 2019 Operating lease cost SG&A and R&D Expenses $ 1,042 $ 708 Short term lease cost (1) R&D Expenses 305 205 Sublease income (2) SG&A and R&D Expenses (45 ) (55 ) Net lease cost $ 1,302 $ 858 (1) Short term lease cost consists of field trial lease agreements with a lease term of 12 months or less. (2) Sublease income is recorded as a reduction to lease expense. Lease Term and Discount Rate December 31, 2020 December 31, 2019 Weighted-average remaining lease term (years) 5.0 2.6 Weighted-average discount rate 6 % 7 % The maturities of the operating lease liabilities as of December 31, 2020 are as follows (in thousands): Years Ending December 31, Amounts 2021 $ 1,089 2022 962 2023 927 2024 817 2025 782 Thereafter 3,396 Total operating lease payments $ 7,973 Less: imputed interest $ 1,867 Total current and noncurrent operating lease liabilities $ 6,106 In March 2021, the Company entered into a lease for office space in Chesterfield, MO, with a lease term of 38 months following the commencement date and no renewal option. The lease is expected to commence in the first quarter of 2021.

Debt

Debt	12 Months Ended
Debt	Dec. 31, 2020
Debt Disclosure [Abstract]
Debt	Note 17. Debt Vehicle Loans During the year ended December 31, 2019, the Company entered into notes payable agreements to finance the purchase of company vehicles. The Company has various vehicle loans that mature in 2024 and have interest rates that range from 7.64% to 8.00%. As of December 31, 2020, the outstanding balance of vehicle loans was $138,000. Paycheck Protection Program Note On April 16, 2020, the Company borrowed $1.1 million and entered into a promissory note for the same amount (the “PPP Note”) under the Paycheck Protection Program (“PPP”) that was established under the Coronavirus Aid Relief, and Economic Security Act (“CARES Act”) of 2020. The PPP Note matures on April 16, 2022, bears an interest rate of 1.00% per year, with interest accruing monthly beginning on November 2, 2020. The Company may prepay the PPP Note at any time prior to maturity with no prepayment penalties. The principal amount of the PPP Note and accrued interest are eligible for forgiveness if the proceeds are used for qualifying expenses, including payroll, rent, and utilities during the eight week period commencing on April 16, 2020. The Company will be obligated to repay any portion of the principal amount of the PPP Note that is not forgiven, together with accrued interest thereon, until such unforgiven portion is paid in full. The Company intends to apply for loan forgiveness within the required timeframe. No assurance is provided that the Company will obtain forgiveness of the PPP Note in whole or in part. As of December 31, 2020, the outstanding balance of the PPP Note was $1.1 million. Promissory Note On June 26, 2020, executed a promissory note (the “Note") in the amount of $2.0 million, payable to MidFirst Bank, a federally chartered savings association (the "Lender"). The Note was issued in accordance with the terms of a Loan Agreement dated as of May 18, 2020 entered into by the Company and the Lender (the “Loan Agreement”) in which the Lender agreed to make advances to the Company from time to time, at any amount up to but not to exceed $2.0 million. Pursuant to the Loan Agreement, the Note accrues interest, adjusted monthly, at a rate equal to the greater of (i) 3.25% and (ii) the sum of (a) the quotient of the LIBOR Index divided by (one minus the reserve requirement set by the Federal Reserve), and (b) 2.50%. consolidated balance sheets as of December 31, 2020. As of December 31, 2020, the outstanding balance of the Note was $2.0 million. On February 26, 2021, the Company repaid the full balance of $2.0 million, and expects to close the line of credit on or around March 31, 2021. Maturities of current and noncurrent debt as of December 31, 2020 Years ending December 31, Amounts 2021 $ 1,141 2022 32 2023 2,035 2024 38 2025 — Thereafter — Total $ 3,246

Income Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	Note 18. Income Taxes The components of loss before income taxes are as follows (in thousands): Year Ended December 31, 2020 2019 Domestic $ (6,150 ) $ (28,871 ) Foreign — — Loss before income taxes $ (6,150 ) $ (28,871 ) The total income tax (benefit) expense for the years ended December 31, 2020 and 2019 was $(124,000) and $2,000, respectively, and is comprised of current state taxes and foreign taxes withheld by governmental agencies outside of the United States, as follows (in thousands): Year Ended December 31, 2020 2019 Current: Federal $ — $ — State (28 ) 2 Foreign 10 — Total current tax (benefit) expense (18 ) 2 Deferred: Federal (84 ) — State (22 ) — Foreign — — Total deferred tax (benefit) expense (106 ) — Total tax (benefit) expense $ (124 ) $ 2 The Company operates in only one federal jurisdiction, the United States. The following is a reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows: Year Ended December 31, 2020 2019 Expected income tax provision at the federal statutory rate 21.0 % 21.0 % State taxes, net of federal benefits 9.4 % 5.3 % Change in valuation allowance (43.8 )% (26.4 )% Transaction costs (2.2 )% — Related offering costs — (0.5 )% Derivative liabilities 22.4 % — Non-Controlling Interest (4.7 )% — Withholding taxes (0.2 )% — Other — 0.6 % Income tax provision 1.9 % — Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, net operating loss carryforwards (“NOLs”) and other tax credits. Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands): As of December 31, 2020 2019 Deferred tax assets: Net operating loss carryforwards $ 15,478 $ 13,267 Unearned revenue 2 11 Stock-based compensation 3,881 3,384 Accrued payroll and benefits 236 224 Research and development credits 16 — Fixed asset basis difference 84 90 Inventory reserve 491 568 Lease liability 1,622 565 Common stock warrant assets — 988 Contingent Consideration 531 — Charitable contributions 3 2 Total deferred tax assets 22,344 19,099 Deferred tax liabilities: Right of use asset (1,548 ) (526 ) Amortizable intangibles (98 ) — Income from Partnerships (13 ) — Other (174 ) — Total deferred tax liabilities (1,833 ) (526 ) Less valuation allowance (20,511 ) (18,573 ) Net deferred tax assets $ — $ — Realization of the deferred tax assets is dependent upon future taxable income, if any, the amount and timing of which are uncertain. Accordingly, the net deferred tax assets have been offset by a valuation allowance. The net valuation allowance increased by $1.9 million during the year ended December 31, 2020 and decreased by $25.9 million during the year ended December 31, 2019. At December 31, 2020, the Company had federal and state NOLs aggregating approximately $55.8 million and $57.2 million, respectively. At December 31, 2020, the utilization of a portion of the federal NOLs is subject to an annual limitation under Section 382 of the Internal Revenue Code (IRC). Of the $193.1 million of federal NOLs generated, $7.2 million was previously determined as unavailable to be utilized within the carryforward period, and $130.5 million is expected to be unavailable due to an ownership change under IRC Section 382 that the Company experienced as a result of the common shares issued in connection with the June 2018 Offering. The Company evaluates deferred tax assets, including the benefit from NOLs, to determine if a valuation allowance is required. Such evaluation is based on consideration of all available evidence using a “more likely than not” standard with significant weight being given to evidence that can be objectively verified. This assessment considers, among other matters, the nature, frequency, and severity of current and cumulative losses; forecasts of future profitability; the length of statutory carryforward periods; the Company’s experience with operating losses; and tax-planning alternatives. The significant piece of objective negative evidence evaluated was the cumulative loss incurred through the year ended December 31, 2020. Given this evidence and the expectation to incur operating losses in the foreseeable future, a full valuation allowance has been recorded against the net deferred tax asset. The Company will continue to maintain a full valuation allowance against the entire amount of its net deferred tax asset, until such time as the Company has determined that the weight of the objectively verifiable positive evidence exceeds that of the negative evidence and it is likely that the Company will be able to utilize all of its net deferred tax asset relating to its federal and state NOL carryforwards. Although the Company has established a full valuation allowance on its net deferred tax asset, for Federal tax losses before 2018 and for all state tax losses, it has not forfeited the right to carryforward tax losses up to 20 years and apply such tax losses against taxable income in such years, thereby reducing its future tax obligations. Federal tax losses generated in 2018 and later do not expire. The Company is subject to taxation in the United States and various state jurisdictions. As of December 31, 2020, the Company’s tax years for 2001 through 2020 are generally subject to examination by the tax authorities. The years are open back to 2001 to the extent the NOLs being carried forward were generated then. As of December 31, 2020, the Company had the following unrecognized tax benefits (in thousands): Year Ended December 31, 2020 2019 Unrecognized tax benefit beginning balance $ — $ — Increases for tax positions taken in prior years 2 — Decreases for tax positions taken in prior years — — Increases for tax positions taken in current years 15 — Settlements — — Unrecognized tax benefit ending balance $ 17 $ — The Company is currently not under audit for federal or state purposes. The Company does not anticipate its total unrecognized tax benefits as of December 31, 2020 will significantly change due to settlement of examination or the expiration of statute of limitations during the next 12 months. The Company is currently unaware of any uncertain tax positions that could result in significant additional payments, accruals or other material deviation in this estimate over the next 12 months.

Retirement Benefits

Retirement Benefits	12 Months Ended
Retirement Benefits	Dec. 31, 2020
Compensation And Retirement Disclosure [Abstract]
Retirement Benefits	Note 19. Retirement Benefits The Company has a 401(k) retirement plan (the “Plan”) available for participation by all regular full-time employees who have completed three months of service with the Company. The Company established the Plan in 2008. The Plan provides for a discretionary matching contribution equal to 50% of the amount of the employee’s salary deduction, not to exceed 3% of the salary per employee. Highly compensated employees are excluded from receiving any discretionary matching contribution. Employees’ rights to employer contributions vest on the one-year anniversary of their date of employment. The Company has the option to make discretionary matching contributions. The Company did not make discretionary matching contributions during the years ended December 31, 2020 and 2019.

Segment Reporting

Segment Reporting	12 Months Ended
Segment Reporting	Dec. 31, 2020
Segment Reporting [Abstract]
Segment and Geographic Information	Note 20. Segment and Geographic Information Management has determined that it has one business activity and operates in one segment as it only reports financial information on an aggregate and consolidated basis to its Chief Executive Officer, who is the Company’s chief operating decision maker. Revenues based on the location of the customers, are as follows (in thousands): Year Ended December 31, 2020 2019 United States $ 761 $ 722 Argentina 6,681 - India 100 7 Africa 106 182 Canada 354 258 Austria 32 - Total $ 8,034 $ 1,169

Net Loss per Share

Net Loss per Share	12 Months Ended
Net Loss per Share	Dec. 31, 2020
Earnings Per Share [Abstract]
Net Loss per Share	Note 21. Net Loss per Share Basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period and excludes any dilutive effects of stock-based awards and warrants. Diluted net loss per share attributable to common stockholders is computed giving effect to all potentially dilutive common shares, including common stock issuable upon exercise of stock options and warrants. As the Company had net losses for the years ended December 31, 2020 and 2019, all potentially dilutive common shares were determined to be anti-dilutive. Securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows (in shares): Year Ended December 31, 2020 2019 Options to purchase common stock 889,759 661,701 Warrants to purchase common stock 7,200,280 4,170,651 Total 8,090,039 4,832,352

Related-Party Transactions

Related-Party Transactions	12 Months Ended
Related-Party Transactions	Dec. 31, 2020
Related Party Transactions [Abstract]
Related-Party Transactions	Note 22. Related Party Transactions The Company’s related parties include Moral Compass Corporation (“MCC”) and the John Sperling Foundation (“JSF”). The rights to the intellectual property owned by Blue Horse Labs, Inc. (“BHL”) were assigned to its sole shareholder, the John Sperling Revocable Trust (“JSRT”) due to BHL’s dissolution and then subsequently to the JSF. The JSF is deemed a related party of the Company because MCC, the Company’s largest stockholder, and the JSF share common officers and directors. Transactions with related parties are reflected in the consolidated financial statements under amounts due to related parties. Outlined below are details of agreements between the Company and its related parties: JSF receives a single digit royalty from the Company when revenue has been collected on product sales or for license payments from third parties that involve certain intellectual property developed under research funding originally from BHL. Royalty fees due to JSF were $80,000 and $40,000 as of December 31, 2020 and December 31, 2019, respectively, and are included in the consolidated balance sheets as amounts due to related parties. The Company currently leases land on the island of Molokai, Hawaii from an entity owned by Kevin Comcowich, the Chair of the Company’s Board of Directors, and his wife. The Company grows hemp on this land to support the operations of its joint venture Archipelago Ventures Hawaii. The original lease was executed in February 2019, covers 10 acres of land, has a term of two years and provides for rent payments of $1,200 per acre per year. In March and April 2020, the Company entered into two lease amendments for two additional 10-acre parcels and two additional 15-acre parcels, at the same lease rate of $1,200 per acre per year, and with a term of two years. The term for all five parcels of leased land ends February 28, 2022. In 2019, the Company engaged a third-party contractor to construct a fence on the property to adhere to the rules of the hemp pilot program. Out of pocket costs to build this fence were approximately $126,400. Mr. Comcowich supplied materials to the contractor and received payments from the contractor totaling approximately $44,000. The Company made lease payments in the amount of $84,000 and $84,000 for the years ended December 31, 2020 and 2019, respectively. For the advisory services provided by Mr. Comcowich to support the operations of the Archipelago joint venture, he was issued 5,273 options to purchase Arcadia common stock for which $9,000 of stock compensation expense was recognized during the year ended December 31, 2020.

Subsequent Events

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	Note 23. Subsequent Events The Company has reviewed and evaluated subsequent events through March 31, 2021, the date the consolidated financial statements were available to be issued. January 2021 PIPE transaction On January 25, 2021, the Company entered into a securities purchase agreement with certain institutional and accredited investors relating to the issuance and sale in a private placement of 7,876,784 shares of Company common stock at a purchase price of $3.1925 per share and warrants exercisable for an aggregate of 3,938,392 shares of Common Stock with an exercise price of $3.13 per Warrant Share. Subject to certain ownership limitations, the Warrants are exercisable upon issuance and will expire on the 5.5-year anniversary of the date of issuance. The Company received cash proceeds of $23.3 million, net of transaction fees. The Company also agreed to grant to Wainwright, or its designees, warrants to purchase up to 5.0% of the aggregate number of shares sold in the Private Placement (393,839 shares) for the services provided as Placement Agent in the transaction. Pursuant to the January 2021 Registration Rights Agreement, the Company filed the January 2021 Registration Statement with the SEC on February 2, 2021 for purposes of registering the sale of the shares of Common Stock issued pursuant to the January 2021 Purchase Agreement and the shares of Common Stock issuable upon exercise of the January 2021 Warrants. The SEC declared the registration statement effective on February 11, 2021.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2020
Organization	Organization Arcadia Biosciences, Inc. (the "Company"), was incorporated in Arizona in 2002 and maintains its headquarters in Davis, California, with additional facilities in Phoenix, Arizona, American Falls, Idaho, Molokai, Hawaii, and Albany, Oregon. The Company was reincorporated in Delaware in March 2015. The Company is a leader in science-based approaches to developing high value crop productivity traits primarily in hemp, wheat, and soybean, designed to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. The Company uses state of the art gene-editing technology and advanced breeding techniques to develop these proprietary innovations which the Company is beginning to monetize through a number of methods including seed and grain sales, product extract sales, trait licensing and royalty agreements. In February 2012, the Company formed Verdeca LLC (“Verdeca,” see Note 9), a limited liability company jointly owned with Bioceres, Inc. (“Bioceres”), a U.S. wholly owned subsidiary of Bioceres, S.A., an Argentine corporation. Bioceres, S.A. is an agricultural investment and development cooperative. On November 12, 2020, the Company entered into a Master Transaction Agreement (“Transaction”) with Bioceres Crop Solutions Corp pursuant to which the Company sold all of its memberships interests it owned in Verdeca to Bioceres, Inc. Verdeca was consolidated by the Company through the date of the Transaction. On August 9, 2019, the Company entered into a joint venture agreement with Legacy Ventures Hawaii, LLC (“Legacy,” see Note 8) to grow, extract, and sell hemp products. The new partnership, Archipelago Ventures Hawaii, LLC (“Archipelago”), combines the Company’s extensive genetic expertise and resources with Legacy’s experience in hemp extraction and sales.
Liquidity, Capital Resources, and Going Concern	Liquidity, Capital Resources, and Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. Since inception, the Company has financed its operations primarily through equity and debt financings. As of December 31, 2020, the Company had an accumulated deficit of $211.8 million, cash and cash equivalents of $14.0 million, restricted cash of $2.0 million, and short-term investments of $11.6 million. For the years ended December 31, 2020 and 2019, the Company had net losses of $6.0 million and $28.9 million, respectively, and net cash used in operations of $30.2 million and $17.2 million, respectively. The Company believes that its existing cash, cash equivalents and investments will be sufficient to meet its anticipated cash requirements for at least through March 2022. The Company may seek to raise additional The Company is closely monitoring how the spread of the novel coronavirus (“COVID-19”) is affecting its business operations and employees. The Company’s targeted revenues have been adversely impacted as hemp growers have been slower to make decisions to purchase hemp seeds due to economic uncertainty and wheat consumer packaged goods companies have been heavily focused on production over R&D evaluation as demand for staples like pasta and flour have increased. The continued spread of the outbreak may further impact the Company’s business, results of operations, and financial condition.
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The consolidated financial statements include the accounts of the Company, Verdeca and Archipelago. All intercompany balances and transactions have been eliminated in consolidation. The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP (“GAAP”), and with the rules of the Securities and Exchange Commission. The Company uses a qualitative approach in assessing the consolidation requirement for variable interest entities ("VIEs"). This approach focuses on determining whether the Company has the power to direct the activities of the VIE that most significantly affect the VIE’s economic performance and whether the Company has the obligation to absorb losses, or the right to receive benefits, that could potentially be significant to the VIE. Up to the date of the sale transaction described in Note 1, the Company has determined that it is the primary beneficiary of Verdeca, which was a VIE. Accordingly, the Company consolidates Verdeca in the consolidated financial statements after eliminating intercompany transactions. The Company evaluates its relationships with its VIEs upon the occurrence of certain significant events that affect the design, structure or other factors pertinent to the primary beneficiary determination. Verdeca had no operations, assets or liabilities as of and for the period ended November 12, 2020 and for the year ended December 31, 2019. For all periods presented, the Company has determined that it is the primary beneficiary of Archipelago, a joint venture, as it has a controlling interest in Archipelago. Accordingly, the Company consolidates Archipelago in the consolidated financial statements after eliminating intercompany transactions. For consolidated joint ventures, the non-controlling partner’s share of the assets, liabilities and operations of the joint venture is included in non-controlling interests as equity of the Company. The non-controlling partner’s interest is generally computed as the joint venture partner’s ownership percentage of Archipelago. Net loss attributable to non-controlling interest of $1,371,000 and $68,000 is recorded as an adjustment to net loss to arrive at net loss attributable to common stockholders for the years ended December 31, 2020 and 2019, respectively. The non-controlling partner’s equity interests are presented as non-controlling interests on the consolidated balance sheets as of December 31, 2020 and 2019.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions in the Company’s consolidated financial statements and notes thereto. Significant estimates and assumptions made by management included the determination of the provision for income taxes, stock-based compensation, fair value of certain equity instruments, and net realizable value of inventory. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. COVID-19 continues to create significant uncertainty and disruption in the global economy and financial markets and could impact estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers any liquid investments with a stated maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents consist of cash on deposit with banks. The Company limits cash investments to financial institutions with high credit standings; therefore, management believes that there is no significant exposure to any credit risk in the Company’s cash and cash equivalents. However, as of December 31, 2020 and 2019, a substantial portion of the Company’s cash in depository accounts is in excess of the federal deposit insurance limits.
Restricted Cash	Restricted Cash Restricted cash consists of funds that are contractually or legally restricted as to usage or withdrawal and have been presented separately from cash and cash equivalents on the consolidated balance sheets
Investments in Debt and Equity Securities	Investments in Debt and Equity Securities Investments in debt and equity securities are carried at fair value and classified as short-term investments. The 1,875,000 shares of common stock of Bioceres Crop Solutions Corp. (“BIOX”) added during the fourth quarter ended December 31, 2020, have a six-months’ trading restriction, expiring on May 12, 2021. Realized and unrealized gains and losses on investment securities are included in other income, net, in the consolidated statements of operations and comprehensive loss. Investment securities are reported as cash and cash equivalent, short-term investments or long-term investments in the consolidated balance sheets based on the nature of the investments and maturity period. Short-term investments have maturities of less than a year and long-term investments have maturities of a year and greater from the balance sheet date. The Company’s equity securities are primarily comprised of shares of BIOX listed on the New York Stock Exchange (“NYSE”). These investments are held in the custody of a major financial institution. Other debt securities consist of U.S. government securities, treasury bills, commercial paper, corporate securities, and money markets.
Other-than-Temporary Impairments on Investment	Other-than-Temporary Impairments on Investment The Company regularly reviews each of its investments for impairment by determining if the investment has sustained an other-than-temporary decline in its value, in which case the investment is written down to its fair value by a charge to earnings. Factors that are considered by the Company in determining whether an other-than-temporary decline in value has occurred include (i) the market value of the investment in relation to its cost basis, (ii) the financial condition of the investment, and (iii) the Company’s intent and ability to retain the investment for a sufficient period of time to allow for recovery of the market value of the investment. As of December 31, 2020 and 2019, there was no impairment of the Company’s investments.
Accounts Receivable	Accounts Receivable Accounts receivable represents amounts owed to the Company from product sales, licenses, royalties and contract research and government grants. The carrying value of the Company’s receivables represents estimated net realizable values. The Company generally does not require collateral and estimates any required allowance for doubtful accounts based on historical collection trends, the age of outstanding receivables, and existing economic conditions. If events or changes in circumstances indicate that specific receivable balances may be impaired, further consideration is given to the collectability of those balances and the allowance is recorded accordingly. Past-due receivable balances are written off when the Company’s internal collection efforts have been unsuccessful in collecting the amounts due. The Company had no amounts reserved for doubtful accounts at December 31, 2020 and 2019 as the Company expected full collections of all accounts receivable balances as of each of these dates.
Inventory	Inventory GoodWheat: Propriety wheat plants are grown, producing seed with a variety of improved nutritional qualities, including high levels of amylose, improved shelf-life, and reduced gluten. The seed is used for subsequent plantings or processed, and sold as GoodWheat seeds, grain, and flour, which the Company refers to collectively as GoodWheat products. Amounts inventoried consist primarily of fees paid to contracted cooperators to grow the crops, costs to process and store harvested seed and grain, and costs to mill the grain into flour. SONOVA® Gamma Linolenic Acid (“GLA”) Safflower Oil: Proprietary safflower plants were grown, producing seed with a high-GLA content. This seed was processed, and is sold as GLA oil, including SONOVA 400 GLA safflower oil and SONOVA Ultra GLA safflower oil, which the Company refers to collectively as SONOVA products. Amounts inventoried consist primarily of fees paid to contracted cooperators to grow the crops and costs to process and store the oil. GoodHemp : Proprietary seeds are grown and used for subsequent plantings and sold as final product to other growers. Amounts in inventory for internally produced hemp seeds consist primarily of labor, supplies and facility costs. The costs to procure seeds from external growers and suppliers are included in inventory, as well. Archipelago : Hemp seeds are purchased from external sources and planted on land leased in Molokai. The costs of purchasing, planting and growing the seed, and harvesting the resulting biomass are captured as inventory, along with the costs to process the biomass into CBD oil. Amounts in inventory for growing biomass primarily consist of labor, supplies and facility costs. The inventories—current line item on the balance sheet represents inventory forecasted to be sold or used in production in the next 12 months, as of the balance sheet date, and consists primarily of the cost of GoodWheat seed, grain, and flour, GLA oil, and hemp seed. The inventories—noncurrent line item on the balance sheet represents inventory expected to be used in production or sold beyond the next 12 months, as of the balance sheet date, and consists primarily of GoodWheat seed and grain, and GLA oil. Raw materials inventories consist primarily of the costs to produce GoodWheat seeds. Goods in process inventories consist of costs to produce GoodHemp seed, hemp seed production costs incurred by Archipelago, grower fees and related costs for soybeans to be transferred to Verdeca, and GoodWheat seed and grain. Finished goods inventories consist of GoodWheat products, GoodHemp seed and GLA oil that are available for sale.
Property and Equipment	Property and Equipment Property and equipment acquisitions are recorded at cost. Provisions for depreciation are calculated using the straight-line method over the following average estimated useful lives of the assets: Years Laboratory equipment 5 Software and computer equipment 3 Machinery and equipment 2-20 Furniture and fixtures 7 Vehicles 5 Leasehold improvements 2-10 * * Leasehold improvements are depreciated over the shorter of the estimated life of the asset or the remaining life of the lease.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company evaluates if events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and identifiable intangible assets may warrant revision or that the remaining balance of these assets may not be recoverable. In evaluating for recoverability, the Company estimates the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. In the event that the balance of any asset exceeds the future undiscounted cash flow estimate, impairment is recognized based on the excess of the carrying amounts of the asset above its estimated fair value. As of December 31, 2020 and 2019, there was no impairment of the Company’s long-lived assets.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. Assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities, are as follows: • Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date. • Level 2 inputs are observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 inputs are unobservable inputs for the asset or liability. The carrying values of the Company’s financial instruments, including cash equivalents, accounts receivable, and accounts payable approximated their fair values due to the short period of time to maturity or repayment.
Concentration of Risk	Concentration of Risk Cash and cash equivalents are maintained with several financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate its credit risks by spreading such risks across multiple counterparties and monitoring the risk profiles of these counterparties.
Customer Concentration	Customer Concentration Significant customers are those that represent greater than 10% of the Company’s total revenues or gross accounts receivable balance at each respective balance sheet date. The Company had three customers that represented 57%, 21% and 12% of accounts receivable, and three customers that represented 47%, 17%, and 15% of accounts receivable, as of December 31, 2020 and 2019, respectively. The Company had one customer that represented 83% of total revenues, and two customers that represented 40% and 15% of total revenues, for the years ended December 31, 2020 and 2019, respectively.
Stock-Based Compensation	Stock-Based Compensation The Company recognizes compensation expense related to its employee stock purchase plan and the cost of stock-based compensation awards on a straight-line basis over the requisite service period, net of estimated forfeitures. Judgment is required in estimating the amount of stock-based awards that will be forfeited prior to vesting. Compensation expense could be revised in subsequent periods if actual forfeitures differ from those estimates. The Company has selected the Black-Scholes option-pricing model and various inputs to estimate the fair value of its stock-based awards. See Note 14 for additional information. Amounts recognized in the consolidated statements of operations and comprehensive loss were as follows (in thousands): Year Ended December 31, 2020 2019 (in thousands) Research and development $ 341 $ 321 Selling, general and administrative 1,701 1,966 Total stock-based compensation $ 2,042 $ 2,287
Income Taxes	Income Taxes The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.
Net Loss per Share	Net Loss per Share Basic net loss per share, which excludes dilution, is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock, such as stock options, convertible promissory notes, convertible preferred stock, redeemable convertible preferred stock and warrants, result in the issuance of common stock which share in the losses of the Company. Certain potential shares of common stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. Such potentially dilutive shares are excluded when the effect would be to reduce the loss per share. Due to net losses, there is no impact on earnings per share calculation in applying the two-class method since the participating securities have no legal requirement to share in any losses.
Revenue Recognition	Revenue Recognition The Company derives its revenues from product revenues, licensing agreements, royalties, contract research agreements, and government grants.
Unearned Revenue	Unearned Revenue The Company defers revenue to the extent that cash received in conjunction with a license agreement, contract or grant exceeds the revenue recognized in accordance with Company policies. During the year ended December 31, 2020, the Company recognized revenue of $54,000 that was included in unearned revenue on the consolidated balance sheet as of December 31, 2019.
Cost of Product Revenues	Cost of Product Revenues Cost of product revenues relates to the sale of SONOVA and GoodWheat products and consists of in-licensing and royalty fees, any adjustments or write-downs to inventory, as well as the cost of raw materials, including inventory and third-party services costs related to procuring, processing, formulating, packaging, and shipping the Company’s products.
Research and Development Expenses	Research and Development Expenses Research and development expenses consist of costs incurred in the discovery, development, and testing of the Company’s products and products in development incorporating the Company’s traits. These expenses consist primarily of employee salaries and benefits, fees paid to subcontracted research providers, fees associated with in-licensing technology, land leased for field trials, chemicals and supplies, and other external expenses. These costs are expensed as incurred.
Change in Fair Value of Contingent Consideration	C hange in Fair Value of Contingent Consideration Change in the fair value of contingent consideration is comprised of the gain associated with the reduction of the contingent liability. See Note 15.
Change in the Estimated Fair Value of Common Stock Warrant Liabilities	C hange in the Estimated Fair Value of Common Stock Warrant Liabilities Change in the estimated fair value of common stock warrant liabilities is comprised of the fair value remeasurement of liability classified common stock warrants. See Note 13.
Product Revenues
Revenue Recognition	Product Revenues Product revenues to date have consisted primarily of sales of SONOVA products, with initial GoodWheat seed sale revenues recognized in the fourth quarter of 2019 and initial GoodHemp seed sale revenues recognized in the fourth quarter of 2020. The Company recognizes revenue from product sales when control of the product is transferred to third-party distributors and manufacturers, collectively “our customers”, which generally occurs upon shipment. Revenues fluctuate depending on the timing of shipments of product to our customers.
License Revenues
Revenue Recognition	License Revenues License revenues to date consist of up-front, nonrefundable license fees, annual license fees, and subsequent milestone payments that the Company receives under the Company’s research and license agreements. The Company recognizes revenue generated from up-front, nonrefundable license fees upon execution of the agreement and recognizes annual license fees when it is probable that a material reversal will not occur. Milestone fees are variable consideration that is initially constrained and recognized only when it is probable that such amounts would not be reversed. The Company assesses when achievement of milestones is probable to determine the timing of revenue recognition for milestone fees
Royalty
Revenue Recognition	Royalty Revenues Royalty revenues from the Company’s agreements with third parties related to GoodWheat products are recognized when the Company can reasonably determine the amounts earned. In most cases, this will be upon notification from the third-party licensee.
Contract Research Revenues
Revenue Recognition	Contract Research Revenues Contract research and government grant revenues consist of amounts earned from performing contracted research primarily related to breeding programs or the genetic engineering of plants for third parties. Contract research revenue is accounted for as a single performance obligation for which revenues are recognized over time using the input method (e.g., costs incurred to date relative to the total estimated costs at completion).
Government Grant Revenues
Revenue Recognition	Government Grant Revenues The Company receives payments from government entities in the form of government grants. Government grant revenue is accounted for as a single performance obligation for which revenues are recognized over time using the input method (e.g., costs incurred to date relative to the total estimated costs at completion). The Company’s obligation with respect to these agreements is to perform the research on a best-efforts basis.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Dec. 31, 2020
Accounting Policies [Abstract]
Summary of Average Estimated Useful Lives of Assets	Provisions for depreciation are calculated using the straight-line method over the following average estimated useful lives of the assets: Years Laboratory equipment 5 Software and computer equipment 3 Machinery and equipment 2-20 Furniture and fixtures 7 Vehicles 5 Leasehold improvements 2-10 * * Leasehold improvements are depreciated over the shorter of the estimated life of the asset or the remaining life of the lease.
Amounts Recognized in Consolidated Statements of Operations and Comprehensive Loss Net	Amounts recognized in the consolidated statements of operations and comprehensive loss were as follows (in thousands): Year Ended December 31, 2020 2019 (in thousands) Research and development $ 341 $ 321 Selling, general and administrative 1,701 1,966 Total stock-based compensation $ 2,042 $ 2,287

Inventory (Tables)

Inventory (Tables)	12 Months Ended
Inventory (Tables)	Dec. 31, 2020
Inventory Disclosure [Abstract]
Summary of Inventories	Inventories, net consist of the following (in thousands): December 31, 2020 December 31, 2019 Raw materials $ 966 $ 67 Goods in process 1,921 188 Finished goods 4,410 1,903 Inventories $ 7,297 $ 2,158

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
Property and Equipment, Net (Tables)	Dec. 31, 2020
Property Plant And Equipment [Abstract]
Summary of Property and Equipment, Net	Property and equipment, net consisted of the following (in thousands): As of December 31, 2020 2019 Laboratory equipment $ 2,951 $ 2,443 Software and computer equipment 591 502 Machinery and equipment 2,046 989 Furniture and fixtures 181 90 Vehicles 428 395 Leasehold improvements 2,229 2,023 Property and equipment, gross 8,426 6,442 Less accumulated depreciation and amortization (4,887 ) (4,643 ) Property and equipment, net $ 3,539 $ 1,799

Investments and Fair Value In_2

Investments and Fair Value Instruments (Tables)	12 Months Ended
Investments and Fair Value Instruments (Tables)	Dec. 31, 2020
Investments And Fair Value Instruments [Abstract]
Summary of Amortized Cost and Fair Value of Investment Securities Portfolio	The following tables summarize the amortized cost and fair value of the investment securities portfolio at December 31, 2020 and December 31, 2019, and the corresponding amounts of unrealized gains and losses recognized in other income, net, in the consolidated statements of operations and comprehensive loss: (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value December 31, 2020 Cash equivalents: Money market funds $ 12,082 $ — $ — $ 12,082 Short-term investments: Corporate securities 10,969 656 — 11,625 Total Assets at Fair Value $ 23,051 $ 656 $ — $ 23,707 (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value December 31, 2019 Cash equivalents: Money market funds $ 6,864 $ — $ — $ 6,864 Commercial paper 900 — — 900 Short-term investments: Corporate securities 3,300 — — 3,300 Treasury bills 1,495 1 — 1,496 Commercial paper 12,119 — — 12,119 Total Assets at Fair Value $ 24,678 $ 1 $ — $ 24,679
Summary of Fair Value of Investment Securities	The fair value of the investment securities at December 31, 2020 were as follows: Fair Value Measurements at December 31, 2020 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 12,082 $ — $ — $ 12,082 Short-term investments: Corporate securities 11,625 — — 11,625 Total Assets at Fair Value $ 23,707 $ — $ — $ 23,707 The fair value of the investment securities at December 31, 2019 were as follows: Fair Value Measurements at December 31, 2019 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 6,864 $ — $ — $ 6,864 Commercial paper — 900 — 900 Short-term investments: Corporate securities — 3,300 — 3,300 Treasury bills 1,496 — — 1,496 Commercial paper — 12,119 — 12,119 Total Assets at Fair Value $ 8,360 $ 16,319 $ — $ 24,679
Summary of Warrant Liabilities Measured and Recorded on Recurring Basis using Black-Scholes Model	T he warrant liabilities were measured and recorded on a recurring basis September 2019 Warrants June 2019 Warrants June 2018 Warrants March 2018 Warrants December 31, 2020 December 31, 2019 December 31, 2020 December 31, 2019 December 31, 2020 December 31, 2019 December 31, 2020 December 31, 2019 Expected term (in years) 4.20 5.20 3.96 4.96 — 3.96 2.22 3.22 Expected volatility 135.0 % 120.0 % 135.0 % 120.0 % — 123.0 % 130.0 % 125.0 % Risk-free interest rate 0.3 % 1.7 % 0.3 % 1.7 % — 1.7 % 0.1 % 1.6 % Expected dividend yield 0 % 0 % 0 % 0 % — 0 % 0 % 0 %
Summary of Changes in Fair Value and Other Adjustments of Liabilities	The following table sets forth the establishment of the Company’s Level 3 liabilities, as well as a summary of the changes in the fair value and other adjustments (in thousands): (Level 3) (Dollars in thousands) Common Stock Warrant Liability - March 2018 Purchase Agreement Common Stock Warrant Liability - June 2018 Offering Common Stock Warrant Liability - June 2019 Offering Common Stock Warrant Liability - September 2019 Offering Contingent Liabilities Total Balance as of December 31, 2018 $ 2,354 $ 2,729 $ — $ — $ 3,000 $ 8,083 Common stock and warrants issued in conjunction with June 2019 Offering — — 4,198 — — $ 4,198 Common stock and warrants issued in conjunction with September 2019 Offering — — — 3,428 — $ 3,428 Change in fair value and other adjustments 2,225 2,715 4,811 (508 ) (1,000 ) $ 8,243 Exercise of warrants - - (7,016 ) - - $ (7,016 ) Balance as of December 31, 2019 $ 4,579 $ 5,444 $ 1,993 $ 2,920 $ 2,000 $ 16,936 Change in fair value and other adjustments (2,277 ) (1,426 ) (1,161 ) (1,706 ) — $ (6,570 ) Exercise of warrants (1,641 ) (4,018 ) — — — $ (5,659 ) ISI acquisition contingent consideration — — — — 280 $ 280 Balance as of December 31, 2020 $ 662 $ — $ 832 $ 1,214 $ 2,280 $ 4,987

Industrial Seed Innovations A_2

Industrial Seed Innovations Acquisition (Tables)	12 Months Ended
Industrial Seed Innovations Acquisition (Tables)	Dec. 31, 2020
Business Combinations [Abstract]
Schedule of Preliminary Allocation of the Purchase Price of ISI Assets Acquired Based on Fair Values	The following table presents the allocation of the purchase price of ISI assets acquired, based on their relative fair values, which have been assessed during the year ended December 31, 2020. Intangible assets will be amortized based on their useful life of five years, and their balance as of December 31, 2020 was $370,000. A deferred tax liability arising from the difference between book purchase price allocation and tax basis has been assessed in the amount of $107,000. Deferred tax liabilities are required to be recorded in purchase accounting independently of whether the acquiror has a valuation allowance on its own net deferred tax assets. As a result, the combined entity now has additional deferred tax liabilities available to reduce the amount of valuation allowance necessary. Future reversals of existing taxable temporary differences are an objective source of future taxable income. Accordingly, the purchase accounting deferred tax liabilities enabled the realization of a portion of the existing deferred tax assets, thus allowing for a reduction in the valuation allowance. The reduction in the valuation allowance is not accounted for as part of the purchase accounting but is recognized in the consolidated statements of operations and comprehensive loss as a discrete tax benefit in the income tax provision. Purchase Price Allocation Inventory $ 511 Intangible assets, net 400 Goodwill 408 Deferred tax liability (107 ) Total consideration allocated $ 1,212

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
Accounts Payable and Accrued Expenses (Tables)	Dec. 31, 2020
Payables And Accruals [Abstract]
Summary of Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses consisted of the following (in thousands): As of December 31, 2020 2019 Accounts payable - trade $ 726 $ 492 Payroll and benefits 1,489 1,290 Inventory 965 1,143 Research and development 45 629 Royalty fees due to unrelated parties 276 226 Consulting 153 397 Rent and utilities 78 23 Audit and tax fees 57 113 Legal 152 138 Other 164 234 Total accounts payable and accrued expenses $ 4,105 $ 4,685

Warrants (Tables)

Warrants (Tables)	12 Months Ended
Warrants (Tables)	Dec. 31, 2020
Warrants And Rights Note Disclosure [Abstract]
Summary of Warrants Issued to Purchase Common Stock	As of December 31, 2020, the Company issued the following warrants to purchase shares of its common stock. These warrants are exercisable any time at the option of the holder until their expiration date. Issuance Date Term Exercise Price Per Share Warrants Exercised during the Year Ended December 31, 2019 Warrants Outstanding at December 31, 2019 Warrants Exercised during the Year Ended December 31, 2020 Warrants Outstanding at December 31, 2020 December 2020 Warrants December 2020 5.5 years $ 3.00 — — — 2,618,658 December 2020 Placement Agent Warrants December 2020 5 years $ 3.82 — — — 130,933 July 2020 Warrants July 2020 5.5 years $ 3.85 — — — 641,416 July 2020 Placement Agent Warrants July 2020 5.5 years $ 4.97 — — — 32,071 May 2020 Warrants May 2020 5 years $ 4.78 — — — 1,392,345 May 2020 Placement Agent Warrants May 2020 5 years $ 6.13 — — — 69,617 March 2020 Service and Performance Warrants March 2020 3 years $ 2.50 — — — 18,350 February 12, 2020 Service and Performance Warrants February 2020 2 years $ 4.71 — — — 150,000 February 3, 2020 Service and Performance Warrants February 2020 2 years $ 4.91 — — — 10,000 September 2019 Placement Agent Warrants September 2019 5 years $ 9.48 — 65,942 — 65,942 August 2019 Service and Performance Warrants August 2019 2 years $ 1.92 — 20,000 — 20,000 July 2019 Service and Performance Warrants July 2019 2 years $ 2.19 — 10,000 — 10,000 June 2019 Placement Agent Warrants June 2019 5 years $ 6.29 — 74,479 — 74,479 April 2019 Service and Performance Warrants April 2019 5 years $ 6.18 — 145,154 — 145,154 June 2018 Placement Agent Warrants June 2018 5 years $ 12.57 — 69,617 — 69,617 March 2018 Placement Agent Warrants March 2018 5 years $ 41.56 — 15,038 — 15,038 Total — 400,230 — 5,463,620
Summary of Key Terms and Activity of Liability Classified Common Stock Warrants	The key terms and activity of the liability classified common stock warrants are summarized as follows: Issuance Date Term Exercise Price Per Share Warrants Exercised during the Year Ended December 31, 2019 Warrants Outstanding at December 31, 2019 Warrants Exercised during the Year Ended December 31, 2020 Warrants Outstanding at December 31, 2020 September 2019 Warrants September 2019 5.5 years $ 7.52 — 659,414 — 659,414 June 2019 Warrants June 2019 5.5 years $ 5.00 1,053,745 435,830 — 435,830 June 2018 Warrants June 2018 5.5 years $ 9.94 — 1,392,345 1,392,345 — March 2018 Warrants March 2018 5 years $ 10.73 — 1,282,832 641,416 641,416 Total 1,053,745 3,770,421 2,033,761 1,736,660

Stock-Based Compensation and _2

Stock-Based Compensation and Employee Stock Purchase Program (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Activity Under Stock Incentive Plans	The following is a summary of stock option information and weighted average exercise prices under the Company’s stock incentive plans (in thousands, except share data and price per share): Shares Subject to Outstanding Options Weighted- Average Exercise Price Per Share Aggregate Intrinsic Value Outstanding — Balance at December 31, 2018 530,044 $ 35.53 $ — Options granted 208,571 5.13 Options exercised (546 ) 4.63 Options forfeited (30,132 ) 33.95 Options expired (46,236 ) 98.69 Outstanding — Balance at December 31, 2019 661,701 21.60 $ 305 Options granted 502,494 4.28 Options exercised — — Options forfeited (174,508 ) 5.91 Options expired (99,928 ) 25.56 Outstanding — Balance at December 31, 2020 889,759 14.46 $ 240 Vested and expected to vest — December 31, 2020 841,991 15.03 $ 240 Exercisable —December 31, 2020 502,973 $ 22.20 $ —
Weighted-Average Fair Value Assumption of Stock Option Awards	The Year Ended December 31, Assumptions 2020 2019 Expected term (years) 6.48 7.04 Expected volatility 134% 99% Risk-free interest rate 1.01% 2.01% Expected dividend yield — —

Leases (Tables)

Leases (Tables)	12 Months Ended
Leases (Tables)	Dec. 31, 2020
Lessee Disclosure [Abstract]
Schedule of Leases	Leases consisted of the following (in thousands): Leases Classification December 31, 2020 December 31, 2019 Assets Operating lease assets Right of use asset $ 5,826 $ 1,963 Total leased assets $ 5,826 $ 1,963 Liabilities Current - Operating Operating lease liability - current $ 717 $ 611 Noncurrent - Operating Operating lease liability - noncurrent 5,389 1,497 Total leased liabilities $ 6,106 $ 2,108 Lease Cost Classification For the Year Ended December 31, 2020 For the Year Ended December 31, 2019 Operating lease cost SG&A and R&D Expenses $ 1,042 $ 708 Short term lease cost (1) R&D Expenses 305 205 Sublease income (2) SG&A and R&D Expenses (45 ) (55 ) Net lease cost $ 1,302 $ 858 (1) Short term lease cost consists of field trial lease agreements with a lease term of 12 months or less. (2) Sublease income is recorded as a reduction to lease expense. Lease Term and Discount Rate December 31, 2020 December 31, 2019 Weighted-average remaining lease term (years) 5.0 2.6 Weighted-average discount rate 6 % 7 %
Schedule of Maturities of Operating Lease Liabilities	The maturities of the operating lease liabilities as of December 31, 2020 are as follows (in thousands): Years Ending December 31, Amounts 2021 $ 1,089 2022 962 2023 927 2024 817 2025 782 Thereafter 3,396 Total operating lease payments $ 7,973 Less: imputed interest $ 1,867 Total current and noncurrent operating lease liabilities $ 6,106

Debt (Tables)

Debt (Tables)	12 Months Ended
Debt (Tables)	Dec. 31, 2020
Debt Disclosure [Abstract]
Schedule of Maturities of Current and Noncurrent Debt	Maturities of current and noncurrent debt as of December 31, 2020 Years ending December 31, Amounts 2021 $ 1,141 2022 32 2023 2,035 2024 38 2025 — Thereafter — Total $ 3,246

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Components of Loss Before Income Taxes	The components of loss before income taxes are as follows (in thousands): Year Ended December 31, 2020 2019 Domestic $ (6,150 ) $ (28,871 ) Foreign — — Loss before income taxes $ (6,150 ) $ (28,871 )
Schedule of Income Tax Expense Comprised of Current State Taxes and Foreign Taxes	The total income tax (benefit) expense for the years ended December 31, 2020 and 2019 was $(124,000) and $2,000, respectively, and is comprised of current state taxes and foreign taxes withheld by governmental agencies outside of the United States, as follows (in thousands): Year Ended December 31, 2020 2019 Current: Federal $ — $ — State (28 ) 2 Foreign 10 — Total current tax (benefit) expense (18 ) 2 Deferred: Federal (84 ) — State (22 ) — Foreign — — Total deferred tax (benefit) expense (106 ) — Total tax (benefit) expense $ (124 ) $ 2
Reconciliation of the Statutory Federal Income Tax Rate	The following is a reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows: Year Ended December 31, 2020 2019 Expected income tax provision at the federal statutory rate 21.0 % 21.0 % State taxes, net of federal benefits 9.4 % 5.3 % Change in valuation allowance (43.8 )% (26.4 )% Transaction costs (2.2 )% — Related offering costs — (0.5 )% Derivative liabilities 22.4 % — Non-Controlling Interest (4.7 )% — Withholding taxes (0.2 )% — Other — 0.6 % Income tax provision 1.9 % —
Deferred Tax Assets and Liabilities	Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands) As of December 31, 2020 2019 Deferred tax assets: Net operating loss carryforwards $ 15,478 $ 13,267 Unearned revenue 2 11 Stock-based compensation 3,881 3,384 Accrued payroll and benefits 236 224 Research and development credits 16 — Fixed asset basis difference 84 90 Inventory reserve 491 568 Lease liability 1,622 565 Common stock warrant assets — 988 Contingent Consideration 531 — Charitable contributions 3 2 Total deferred tax assets 22,344 19,099 Deferred tax liabilities: Right of use asset (1,548 ) (526 ) Amortizable intangibles (98 ) — Income from Partnerships (13 ) — Other (174 ) — Total deferred tax liabilities (1,833 ) (526 ) Less valuation allowance (20,511 ) (18,573 ) Net deferred tax assets $ — $ —
Schedule of Unrecognized Tax Benefits	As of December 31, 2020, the Company had the following unrecognized tax benefits (in thousands): Year Ended December 31, 2020 2019 Unrecognized tax benefit beginning balance $ — $ — Increases for tax positions taken in prior years 2 — Decreases for tax positions taken in prior years — — Increases for tax positions taken in current years 15 — Settlements — — Unrecognized tax benefit ending balance $ 17 $ —

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
Segment Reporting (Tables)	Dec. 31, 2020
Segment Reporting [Abstract]
Summary of Revenues Based on Location of Customers	Revenues based on the location of the customers, are as follows (in thousands): Year Ended December 31, 2020 2019 United States $ 761 $ 722 Argentina 6,681 - India 100 7 Africa 106 182 Canada 354 258 Austria 32 - Total $ 8,034 $ 1,169

Net Loss per Share (Tables)

Net Loss per Share (Tables)	12 Months Ended
Net Loss per Share (Tables)	Dec. 31, 2020
Earnings Per Share [Abstract]
Schedule of Securities Not Included in Diluted per Share Calculations	Securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows (in shares): Year Ended December 31, 2020 2019 Options to purchase common stock 889,759 661,701 Warrants to purchase common stock 7,200,280 4,170,651 Total 8,090,039 4,832,352

Description of Business - Addit

Description of Business - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Place of incorporation	Arizona
Year of incorporation	2002
Place of reincorporation	Delaware
Date of reincorporation	2015-03
Accumulated deficit	$ (211,825)	$ (207,171)
Cash and cash equivalents	14,042	8,417
Restricted cash	2,001
Short-term investments	11,625	16,915
Net losses	(6,026)	(28,873)
Net cash used in operations	$ (30,218)	$ (17,198)

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	Nov. 12, 2020	Dec. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Accounting Policies [Line Items]
VIEs Operations			$ (12,778,000)	$ (19,381,000)
Net loss attributable to noncontrolling interest			1,371,000	68,000
Reserved for doubtful accounts		$ 0	0	0
Impairment of long-lived assets			0	$ 0
Revenue recognized			$ 54,000
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Customer One [Member]
Accounting Policies [Line Items]
Concentration risk percentage			57.00%	47.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Customer Two [Member]
Accounting Policies [Line Items]
Concentration risk percentage			21.00%	17.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Customer Three [Member]
Accounting Policies [Line Items]
Concentration risk percentage			12.00%	15.00%
Customer Concentration Risk [Member] \| Total Revenue [Member] \| Customer One [Member]
Accounting Policies [Line Items]
Concentration risk percentage			83.00%	40.00%
Customer Concentration Risk [Member] \| Total Revenue [Member] \| Customer Two [Member]
Accounting Policies [Line Items]
Concentration risk percentage				15.00%
Limagrain Cereal Seeds LLC [Member]
Accounting Policies [Line Items]
Impairment of equity method investments			$ 0	$ 0
Short-term Investments [Member] \| Bioceres Crop Solutions [Member]
Accounting Policies [Line Items]
Shares of common stock receivable from sale of interest in joint venture		1,875,000
Short-term investments, trading restriction period		6 months
Short-term investments, trading restriction expiry period		May 12, 2021
Verdeca [Member]
Accounting Policies [Line Items]
VIEs Operations	$ 0			0
VIEs assets or liabilities	$ 0			$ 0

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Average Estimated Useful Lives of Assets (Detail)	12 Months Ended
	Dec. 31, 2020
Laboratory equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	5 years
Software and computer equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	3 years
Machinery and equipment [Member] \| Minimum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	2 years
Machinery and equipment [Member] \| Maximum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	20 years
Furniture and fixtures [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	7 years
Vehicles [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	5 years
Leasehold improvements [Member] \| Minimum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	2 years
Leasehold improvements [Member] \| Maximum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	10 years

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Amounts Recognized in Consolidated Statements of Operations and Comprehensive Loss Net (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation	$ 2,042	$ 2,287
Research and Development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation	341	321
Selling, General and Administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation	$ 1,701	$ 1,966

Recent Accounting Pronounceme_2

Recent Accounting Pronouncements - Additional Information (Detail)	Dec. 31, 2020
ASU 2016-02
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true
Change in accounting principle, accounting standards update, adoption date	Jan. 1, 2019
ASU 2016-15
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true
Change in accounting principle, accounting standards update, adoption date	Jan. 1, 2019
Change in accounting principle, accounting standards update, immaterial effect [true false]	true
ASU 2018-13
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true
Change in accounting principle, accounting standards update, adoption date	Jan. 1, 2020
ASU 2018-07
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true
Change in accounting principle, accounting standards update, adoption date	Jan. 1, 2019
Change in accounting principle, accounting standards update, immaterial effect [true false]	true

Inventory - Additional Informat

Inventory - Additional Information (Detail) - USD ($)	12 Months Ended
Inventory - Additional Information (Detail) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Write-downs of wheat inventories, hemp seed inventories, and prepaid production	$ 4,300,000	$ 304,000

Inventory - Summary of Inventor

Inventory - Summary of Inventories (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 966	$ 67
Goods in process	1,921	188
Finished goods	4,410	1,903
Inventories	$ 7,297	$ 2,158

Property and Equipment, Net - S

Property and Equipment, Net - Summary of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 8,426	$ 6,442
Less accumulated depreciation and amortization	(4,887)	(4,643)
Property and equipment, net	3,539	1,799
Laboratory equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	2,951	2,443
Software and computer equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	591	502
Machinery and equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	2,046	989
Furniture and fixtures [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	181	90
Vehicles [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	428	395
Leasehold improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 2,229	$ 2,023

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property Plant And Equipment [Line Items]
Depreciation expense	$ 632,000	$ 194,000
Property and equipment, gross	8,426,000	6,442,000
Construction in Progress [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 239,000	$ 1,014,000

Investments and Fair Value In_3

Investments and Fair Value Instruments - Summary of Amortized Cost and Fair Value of Investment Securities Portfolio (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 23,051	$ 24,678
Unrealized Gains	656	1
Unrealized Losses	0	0
Estimated Fair Value	23,707	24,679
Cash Equivalents [Member] \| Money Market Funds [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	12,082	6,864
Unrealized Gains	0	0
Unrealized Losses	0	0
Estimated Fair Value	12,082	6,864
Cash Equivalents [Member] \| Commercial Paper [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		900
Unrealized Gains		0
Unrealized Losses		0
Estimated Fair Value		900
Short-term Investments [Member] \| Commercial Paper [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		12,119
Unrealized Gains		0
Unrealized Losses		0
Estimated Fair Value		12,119
Short-term Investments [Member] \| Treasury Bills [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		1,495
Unrealized Gains		1
Unrealized Losses		0
Estimated Fair Value		1,496
Short-term Investments [Member] \| Corporate Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	10,969	3,300
Unrealized Gains	656	0
Unrealized Losses	0	0
Estimated Fair Value	$ 11,625	$ 3,300

Investments and Fair Value In_4

Investments and Fair Value Instruments - Additional Information (Detail)	Dec. 31, 2020USD ($)
Investments Debt And Equity Securities [Abstract]
Investment in continuous unrealized loss position for more than twelve months	$ 0

Investments and Fair Value In_5

Investments and Fair Value Instruments - Summary of Fair Value of Investments Securities (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Assets at Fair Value
Total Assets at Fair Value	$ 23,707	$ 24,679
Treasury Bills [Member]
Assets at Fair Value
Short-term investments		1,496
Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	12,082	6,864
Corporate Securities [Member]
Assets at Fair Value
Short-term investments	11,625	3,300
Commercial Paper [Member]
Assets at Fair Value
Cash equivalents		900
Short-term investments		12,119
Level 1 [Member]
Assets at Fair Value
Total Assets at Fair Value	23,707	8,360
Level 1 [Member] \| Treasury Bills [Member]
Assets at Fair Value
Short-term investments		1,496
Level 1 [Member] \| Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	12,082	6,864
Level 1 [Member] \| Corporate Securities [Member]
Assets at Fair Value
Short-term investments	11,625	0
Level 1 [Member] \| Commercial Paper [Member]
Assets at Fair Value
Cash equivalents		0
Short-term investments		0
Level 2 [Member]
Assets at Fair Value
Total Assets at Fair Value	0	16,319
Level 2 [Member] \| Treasury Bills [Member]
Assets at Fair Value
Short-term investments		0
Level 2 [Member] \| Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	0	0
Level 2 [Member] \| Corporate Securities [Member]
Assets at Fair Value
Short-term investments	0	3,300
Level 2 [Member] \| Commercial Paper [Member]
Assets at Fair Value
Cash equivalents		900
Short-term investments		12,119
Level 3 [Member]
Assets at Fair Value
Total Assets at Fair Value	0	0
Level 3 [Member] \| Treasury Bills [Member]
Assets at Fair Value
Short-term investments		0
Level 3 [Member] \| Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	0	0
Level 3 [Member] \| Corporate Securities [Member]
Assets at Fair Value
Short-term investments	$ 0	0
Level 3 [Member] \| Commercial Paper [Member]
Assets at Fair Value
Cash equivalents		0
Short-term investments		$ 0

Investments and Fair Value In_6

Investments and Fair Value Instruments - Summary of Warrant Liabilities Measured and Recorded on Recurring Basis using Black-Scholes Model (Detail) - Common Stock Warrant Liability [Member] - Level 3 [Member]	Dec. 31, 2020	Dec. 31, 2019
Expected Term [Member] \| September 2019 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Expected term (in years)	4 years 2 months 12 days	5 years 2 months 12 days
Expected Term [Member] \| June 2019 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Expected term (in years)	3 years 11 months 15 days	4 years 11 months 15 days
Expected Term [Member] \| March 2018 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Expected term (in years)	2 years 2 months 19 days	3 years 2 months 19 days
Expected Term [Member] \| June 2018 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Expected term (in years)	0 years	3 years 11 months 15 days
Expected Volatility [Member] \| September 2019 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	135	120
Expected Volatility [Member] \| June 2019 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	135	120
Expected Volatility [Member] \| March 2018 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	130	125
Expected Volatility [Member] \| June 2018 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input		123
Risk-Free Interest Rate [Member] \| September 2019 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.3	1.7
Risk-Free Interest Rate [Member] \| June 2019 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.3	1.7
Risk-Free Interest Rate [Member] \| March 2018 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0.1	1.6
Risk-Free Interest Rate [Member] \| June 2018 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input		1.7
Expected Dividend Yield [Member] \| September 2019 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0	0
Expected Dividend Yield [Member] \| June 2019 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0	0
Expected Dividend Yield [Member] \| March 2018 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	0	0
Expected Dividend Yield [Member] \| June 2018 Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input		0

Investments and Fair Value In_7

Investments and Fair Value Instruments - Summary of Changes in Fair Value and Other Adjustments of Liabilities (Detail) - Level 3 [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	$ 16,936	$ 8,083
Change in fair value and other adjustments	(6,570)	8,243
Exercise of warrants	(5,659)	(7,016)
ISI acquisition contingent consideration	280	0
Ending Balance	4,987	16,936
Common Stock Warrant Liability [Member] \| Purchase Agreement [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	4,579	2,354
Change in fair value and other adjustments	(2,277)	2,225
Exercise of warrants	(1,641)	0
ISI acquisition contingent consideration	0	0
Ending Balance	662	4,579
Common Stock Warrant Liability [Member] \| June 2018 Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	5,444	2,729
Change in fair value and other adjustments	(1,426)	2,715
Exercise of warrants	(4,018)	0
ISI acquisition contingent consideration	0	0
Ending Balance	0	5,444
Common Stock Warrant Liability [Member] \| June 2019 Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	1,993	0
Common stock and warrants issued		4,198
Change in fair value and other adjustments	(1,161)	4,811
Exercise of warrants	0	(7,016)
ISI acquisition contingent consideration	0	0
Ending Balance	832	1,993
Common Stock Warrant Liability [Member] \| September 2019 Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	2,920	0
Common stock and warrants issued		3,428
Change in fair value and other adjustments	(1,706)	(508)
Exercise of warrants	0	0
ISI acquisition contingent consideration	0	0
Ending Balance	1,214	2,920
Contingent Liabilities [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	2,000	3,000
Change in fair value and other adjustments	0	(1,000)
Exercise of warrants	0	0
ISI acquisition contingent consideration	280	0
Ending Balance	$ 2,280	$ 2,000

Industrial Seed Innovations A_3

Industrial Seed Innovations Acquisition - Additional Information (Detail)	Aug. 21, 2020USD ($)Installmentshares	Aug. 31, 2020USD ($)shares	Dec. 31, 2020USD ($)InstallmentTermshares	Dec. 31, 2019USD ($)
Business Acquisition [Line Items]
Revenues			$ 8,034,000	$ 1,169,000
Intangible assets			$ 370,000
Existence of option to extend			true
Lease option to extend, description			Some leases (the Davis office, warehouse, greenhouses and a copy machine) include one or more options to renew, with renewal terms that can extend the lease term from one to six years.
Maximum [Member]
Business Acquisition [Line Items]
Operating leases, term of contract			5 years
Option to extend lease, term			6 years
Minimum [Member]
Business Acquisition [Line Items]
Operating leases, term of contract			1 year
Option to extend lease, term			1 year
Industrial Seed Innovations [Member]
Business Acquisition [Line Items]
Purchase price consideration		$ 1,212,000
Cash paid for Acquisition		500,000
Business combination, equity interest issuable, value		$ 432,000
Remaining amount paid in multiple installments	$ 280,000		$ 280,000
Revenues			$ 0
Useful life of intangible assets amortized			5 years
Intangible assets			$ 370,000
Deferred tax liability			$ 107,000
Operating leases, term of contract			3 years
Existence of option to extend			true
Lease option to extend, description			The lease was effective upon the execution of the definitive acquisition agreement and has a term of 3 years with the option to renew for three additional 3-year terms.
Number of lease renewal term \| Term			3
Option to extend lease, term			3 years
Industrial Seed Innovations [Member] \| Selling, General and Administrative Expenses [Member]
Business Acquisition [Line Items]
Acquisition related costs			$ 67,000
Common Stock [Member] \| Industrial Seed Innovations [Member]
Business Acquisition [Line Items]
Business combination, equity interest issuable, shares \| shares		132,626
Number of annual installment of common stock shares payable \| Installment	2		2
Common Stock [Member] \| Industrial Seed Innovations [Member] \| Revenue Milestone in 2021 [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Business combination, equity interest issuable upon achievement of revenue milestone \| shares	132,626		132,626
Common Stock [Member] \| Industrial Seed Innovations [Member] \| Revenue Milestone in 2022 [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Business combination, equity interest issuable upon achievement of revenue milestone \| shares	132,626		132,626

Industrial Seed Innovations A_4

Industrial Seed Innovations Acquisition - Schedule of Preliminary Allocation of the Purchase Price of ISI Assets Acquired Based on Fair Values (Details)	Dec. 31, 2020USD ($)
Business Acquisition [Line Items]
Goodwill	$ 408,000
Industrial Seed Innovations [Member]
Business Acquisition [Line Items]
Inventory	511,000
Intangible assets, net	400,000
Goodwill	408,000
Deferred tax liability	(107,000)
Total consideration allocated	$ 1,212,000

Consolidated Joint Venture - Ad

Consolidated Joint Venture - Additional Information (Detail)	Aug. 09, 2019Individual	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Schedule Of Equity Method Investments [Line Items]
Net loss attributable to noncontrolling interest		$ 1,371,000	$ 68,000
Arcadia Biosciences, Inc [Member] \| Archipelago Ventures Hawaii, LLC [Member]
Schedule Of Equity Method Investments [Line Items]
Number of individuals appointed \| Individual	2
Joint venture interest percentage		50.75%
Capital contributions		$ 2,336,000
Legacy Ventures Hawaii, LLC [Member] \| Archipelago Ventures Hawaii, LLC [Member]
Schedule Of Equity Method Investments [Line Items]
Number of individuals appointed \| Individual	2
Joint venture interest percentage		49.25%
Capital contributions		$ 2,267,000

Verdeca-BIOX Transactions - Add

Verdeca-BIOX Transactions - Additional Information (Detail) - USD ($)	Nov. 12, 2020	Dec. 31, 2020	Dec. 31, 2019
Variable Interest Entity [Line Items]
Cash receivable from sale of interest in joint venture		$ 3,153,000
Gain on sale of membership interests in Verdeca		8,814,000
Inventory contributed		3,812,000	$ 1,794,000
Revenues		8,034,000	1,169,000
Corporate securities		4,318,000
Accounts receivable		1,406,000	602,000
License
Variable Interest Entity [Line Items]
Revenues		$ 6,801,000	$ 67,000
Verdeca LLC [Member] \| Bioceres Crop Solutions [Member] \| Master Transaction Agreement [Member]
Variable Interest Entity [Line Items]
Cash receivable from sale of interest in joint venture	$ 5,000,000
Shares of common stock receivable from sale of interest in joint venture	1,875,000
Additional cash receivable for transaction expenses and fees	$ 1,000,000
Additional cash receivable from sale of interest in joint venture	$ 2,000,000
Sale of interest in joint venture, description of transaction		BIOX will also pay the Company an additional (i) $1,000,000 payable in five equal monthly payments beginning on December 12, 2020 for transaction expenses and fees and (ii) $2,000,000 payable in four equal quarterly payments with the first payment commencing within thirty days of either BIOX reaching commercial plantings of at least 200,000 hectares of Haab 4 soybeans (“HB4”) or if China approves the HB4 soybean trait for “food and feed”.
Percentage of royalty payments on net revenues	6.00%
Percentage of royalty payments on net revenues received from sales of licensed wheat products	25.00%
Sale of interest in joint venture, fixed consideration agreed amount	$ 16,968,750
Fixed consideration allocated to sale of membership interest	10,288,000
Corporate securities received allocated to sale of member ship interest	$ 6,650,000
Gain on sale of membership interests in Verdeca		$ 8,814,000
Inventory contributed		1,474,000
Accounts receivable		800,000
Restricted period on sale or transfer of common stock	180 days
Verdeca LLC [Member] \| Bioceres Crop Solutions [Member] \| Master Transaction Agreement [Member] \| License
Variable Interest Entity [Line Items]
Revenues		6,680,000
Corporate securities		$ 4,318,000
Verdeca LLC [Member] \| Bioceres Crop Solutions [Member] \| Master Transaction Agreement [Member] \| Maximum [Member]
Variable Interest Entity [Line Items]
Technology royalty revenue receivable on trait fees, from sale of interest in joint venture	$ 10,000,000

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Payables And Accruals [Abstract]
Accounts payable - trade	$ 726	$ 492
Payroll and benefits	1,489	1,290
Inventory	965	1,143
Research and development	45	629
Royalty fees due to unrelated parties	276	226
Consulting	153	397
Rent and utilities	78	23
Audit and tax fees	57	113
Legal	152	138
Other	164	234
Total accounts payable and accrued expenses	$ 4,105	$ 4,685

Collaborative Arrangements - Ad

Collaborative Arrangements - Additional Information (Detail)	1 Months Ended
	Aug. 31, 2017
Collaborative Arrangements [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contractual agreement month and year	2017-08

Equity Financing - Additional I

Equity Financing - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended					12 Months Ended
	Dec. 31, 2020	Sep. 30, 2019	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2020
Maximum [Member]
Class Of Warrant Or Right [Line Items]
Proceeds from issuance, aggregate offering prices						$ 50
March 2018 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued					1,201,634
Warrant issued, shares of common stock called by warrant					1,282,832
Warrants issued, exercise price					$ 10.7258
June 2018 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued				1,392,345
Proceeds from issuance of common stock and warrants gross				$ 14
Offering closing period				Jun. 14, 2018
June 2018 Purchase Agreement [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant				1,392,345
Warrants issued, exercise price				$ 9.94
Warrants expiration period				5 years 6 months
June 2019 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued			1,489,575
Proceeds from issuance of common stock and warrants gross			$ 7.5
Offering closing period			Jun. 14, 2019
June 2019 Purchase Agreement [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant			1,489,575
Warrants issued, exercise price			$ 5
Warrants expiration period			5 years 6 months
September 2019 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued		1,318,828
Proceeds from issuance of common stock and warrants gross		$ 10
Offering closing period		Sep. 5, 2019
September 2019 Purchase Agreement [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant		659,414
Warrants issued, exercise price		$ 7.52
Warrants expiration period		5 years 6 months
December 2020 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued	2,618,658
Proceeds from issuance of common stock and warrants gross	$ 8
Offering closing period	Dec. 22, 2020
December 2020 Purchase Agreement [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant	2,618,658					2,618,658
Warrants issued, exercise price	$ 3					$ 3
Warrants expiration period	5 years 6 months
June 2018 Placement Agent Warrants [Member] \| June 2018 Purchase Agreement [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant				69,617
Warrants issued, exercise price				$ 12.568
Warrant, exercisable term				5 years
June 2019 Placement Agent Warrants [Member] \| June 2019 Purchase Agreement [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant			74,479
Warrants issued, exercise price			$ 6.2938
Warrant, exercisable term			5 years
September 2019 Placement Agent Warrants [Member] \| September 2019 Purchase Agreement [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant		65,942
Warrants issued, exercise price		$ 9.4781
Warrant, exercisable term		5 years
December 2020 Placement Agent Warrants [Member] \| December 2020 Purchase Agreement [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant	130,933					130,933
Warrants issued, exercise price	$ 3.8188					$ 3.8188
Warrant, exercisable term	5 years
March 2018 Private Placement [Member] \| March 2018 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Shares of common stock issued					300,752
Warrant issued, shares of common stock called by warrant					300,752
Warrants issued, exercise price					$ 45.75
Warrants expiration period					5 years
Proceeds from issuance of common stock and warrants gross					$ 10
March 2018 Private Placement [Member] \| March 2018 Placement Agent Warrants [Member] \| March 2018 Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Warrant issued, shares of common stock called by warrant					15,038
Warrants issued, exercise price					$ 41.5625
Warrant, exercisable term					5 years

Warrants - Additional Informati

Warrants - Additional Information (Detail)	1 Months Ended		3 Months Ended		12 Months Ended
Warrants - Additional Information (Detail)	Jul. 31, 2020USD ($)$ / sharesshares	May 31, 2020USD ($)$ / sharesshares	Sep. 30, 2020USD ($)	Jun. 30, 2020USD ($)	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)
Class Of Warrant Or Right [Line Items]
Gross proceeds from warrants exercise					$ 9,372,000	$ 5,269,000
July 2020 Warrant Exercise Transaction [Member]
Class Of Warrant Or Right [Line Items]
Gain (loss) on extinguishment of warrant liability			$ (682,000)
July 2020 Warrant Exercise Transaction [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued, exercise price \| $ / shares	$ 3.85
Warrant issued, shares of common stock called by warrant \| shares	641,416
Warrant, exercisable term	5 years 6 months
Value of warrants	$ 2,100,000
July 2020 Warrant Exercise Transaction [Member] \| Warrants [Member] \| Expected Volatility [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input	126
July 2020 Warrant Exercise Transaction [Member] \| Warrants [Member] \| Stock Price [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input	3.73
July 2020 Warrant Exercise Transaction [Member] \| Warrants [Member] \| Risk-Free Interest Rate [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input	0.35
May 2020 Warrant Exercise Transaction [Member]
Class Of Warrant Or Right [Line Items]
Gain (loss) on extinguishment of warrant liability				$ 47,000
May 2020 Warrant Exercise Transaction [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued, exercise price \| $ / shares		$ 4.775
Warrant issued, shares of common stock called by warrant \| shares		1,392,345
Warrant, exercisable term		5 years
Value of warrants		$ 4,400,000
May 2020 Warrant Exercise Transaction [Member] \| Warrants [Member] \| Expected Volatility [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input		128
May 2020 Warrant Exercise Transaction [Member] \| Warrants [Member] \| Stock Price [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input		3.81
May 2020 Warrant Exercise Transaction [Member] \| Warrants [Member] \| Risk-Free Interest Rate [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input		0.38
March 2018 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Investors exercised warrants and purchase shares of common stock \| shares					641,416
Warrants issued, exercise price \| $ / shares					$ 10.73
March 2018 Warrants [Member] \| July 2020 Warrant Exercise Transaction [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Investors exercised warrants and purchase shares of common stock \| shares	641,416
Warrants issued, exercise price \| $ / shares	$ 3.975
Gross proceeds from warrants exercise	$ 2,600,000
June 2018 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Investors exercised warrants and purchase shares of common stock \| shares					1,392,345
Warrants issued, exercise price \| $ / shares					$ 9.94
June 2018 Warrants [Member] \| May 2020 Warrant Exercise Transaction [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Investors exercised warrants and purchase shares of common stock \| shares		1,392,345
Warrants issued, exercise price \| $ / shares		$ 4.90
Gross proceeds from warrants exercise		$ 6,800,000
Placement Agent [Member] \| July 2020 Warrant Exercise Transaction [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued, exercise price \| $ / shares	$ 4.969
Warrant issued, shares of common stock called by warrant \| shares	32,071
Warrant, exercisable term	5 years 6 months
Value of warrants	$ 101,000
Placement Agent [Member] \| May 2020 Warrant Exercise Transaction [Member] \| Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants issued, exercise price \| $ / shares		$ 6.125
Warrant issued, shares of common stock called by warrant \| shares		69,617
Warrant, exercisable term		5 years
Value of warrants		$ 215,000

Warrants - Summary of Warrants

Warrants - Summary of Warrants Issued to Purchase Common Stock (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Class Of Warrant Or Right [Line Items]
Warrants Outstanding	5,463,620	400,230
December 2020 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-12
Term	5 years 6 months
Exercise Price Per Share	$ 3
Warrants Outstanding	2,618,658
December 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-12
Term	5 years
Exercise Price Per Share	$ 3.82
Warrants Outstanding	130,933
July 2020 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-07
Term	5 years 6 months
Exercise Price Per Share	$ 3.85
Warrants Outstanding	641,416
July 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-07
Term	5 years 6 months
Exercise Price Per Share	$ 4.97
Warrants Outstanding	32,071
May 2020 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-05
Term	5 years
Exercise Price Per Share	$ 4.78
Warrants Outstanding	1,392,345
May 2020 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-05
Term	5 years
Exercise Price Per Share	$ 6.13
Warrants Outstanding	69,617
March 2020 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-03
Term	3 years
Exercise Price Per Share	$ 2.50
Warrants Outstanding	18,350
February 12, 2020 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-02
Term	2 years
Exercise Price Per Share	$ 4.71
Warrants Outstanding	150,000
February 3, 2020 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2020-02
Term	2 years
Exercise Price Per Share	$ 4.91
Warrants Outstanding	10,000
September 2019 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-09
Term	5 years
Exercise Price Per Share	$ 9.48
Warrants Outstanding	65,942	65,942
August 2019 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-08
Term	2 years
Exercise Price Per Share	$ 1.92
Warrants Outstanding	20,000	20,000
July 2019 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-07
Term	2 years
Exercise Price Per Share	$ 2.19
Warrants Outstanding	10,000	10,000
June 2019 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-06
Term	5 years
Exercise Price Per Share	$ 6.29
Warrants Outstanding	74,479	74,479
April 2019 Service and Performance Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-04
Term	5 years
Exercise Price Per Share	$ 6.18
Warrants Outstanding	145,154	145,154
June 2018 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2018-06
Term	5 years
Exercise Price Per Share	$ 12.57
Warrants Outstanding	69,617	69,617
March 2018 Placement Agent Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2018-03
Term	5 years
Exercise Price Per Share	$ 41.56
Warrants Outstanding	15,038	15,038

Warrants - Summary of Key Terms

Warrants - Summary of Key Terms and Activity of Liability Classified Common Stock Warrants (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Class Of Warrant Or Right [Line Items]
Warrants Outstanding	5,463,620	400,230
September 2019 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-09
Term	5 years 6 months
Exercise Price Per Share	$ 7.52
Warrants Outstanding	659,414	659,414
June 2019 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2019-06
Term	5 years 6 months
Exercise Price Per Share	$ 5
Warrants Exercised during the Year		1,053,745
Warrants Outstanding	435,830	435,830
June 2018 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2018-06
Term	5 years 6 months
Exercise Price Per Share	$ 9.94
Warrants Exercised during the Year	1,392,345
Warrants Outstanding		1,392,345
March 2018 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Issuance Date	2018-03
Term	5 years
Exercise Price Per Share	$ 10.73
Warrants Exercised during the Year	641,416
Warrants Outstanding	641,416	1,282,832
September 2019, June 2019, June 2018 and March 2018 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Warrants Exercised during the Year	2,033,761	1,053,745
Warrants Outstanding	1,736,660	3,770,421

Stock-Based Compensation and _3

Stock-Based Compensation and Employee Stock Purchase Program - Additional Information (Detail)	Aug. 23, 2019	Aug. 22, 2019	May 20, 2015shares	May 14, 2015	Jun. 30, 2019shares	Sep. 30, 2018	Dec. 31, 2020USD ($)IncentivePlan$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity incentive plans \| IncentivePlan							2
Total number of options outstanding							889,759	661,701	530,044
Intrinsic value of options exercised \| $							$ 0	$ 0
Unrecognized compensation cost related to unvested stock-based compensation grants \| $							$ 700,000
Weighted-average remaining recognition period							2 years 9 months 7 days
Stock-based compensation \| $							$ 2,042,000	$ 2,287,000
Weighted-average estimated grant-date fair value of stock options granted \| $ / shares							$ 3.80	$ 5.13
2015 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of shares reserved for issuance under plan							105,036
Stock-based compensation \| $							$ 47,000	$ 16,000
Percentage in payroll deductions to acquire shares of common stock				15.00%
Purchase plan offering period				6 months
Employees are able to purchase company's common stock on first trading day of offering period, percentage				85.00%
Issuance of common stock pursuant to employee stock purchase plan							35,056
First offering period, start date				May 14, 2015
First offering period, end date				Feb. 1, 2016
Separation Agreement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exercisable period	2 years	90 days
Separation Agreement [Member] \| Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation \| $								$ 438,000
2015 Omnibus Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Terms under the plan							The 2015 Plan became effective upon the Company’s IPO in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 154,387 shares of common stock reserved for future issuance, which included 10,637 that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan.
Total number of shares reserved for issuance under plan			154,387				1,047,243
Options vesting period			4 years			2 years
Additional shares authorized for issuance under the plan					120,000
Common stock available for future grant							157,484
Total number of options outstanding							870,587	616,472
2006 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of shares reserved for issuance under plan			10,637
Total number of options outstanding							19,172	45,229
Maximum [Member] \| 2015 Omnibus Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options exercisable period			10 years

Stock-Based Compensation and _4

Stock-Based Compensation and Employee Stock Purchase Program - Summary of Activity Under Stock Incentive Plans (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Shares Subject to Outstanding, Beginning Balance	661,701	530,044
Shares Subject to Outstanding, Options granted	502,494	208,571
Shares Subject to Outstanding, Options exercised		(546)
Shares Subject to Outstanding, Options Forfeited	(174,508)	(30,132)
Shares Subject to Outstanding, Options Expired	(99,928)	(46,236)
Shares Subject to Outstanding, Ending Balance	889,759	661,701
Shares Subject to Outstanding, Vested and expected to vest	841,991
Shares Subject to Outstanding, Exercisable	502,973
Weighted-Average Exercise Price Per Share, Outstanding Beginning Balance	$ 21.60	$ 35.53
Weighted-Average Exercise Price Per Share, Options granted	4.28	5.13
Weighted-Average Exercise Price Per Share, Options exercised		4.63
Weighted-Average Exercise Price Per Share, Options forfeited	5.91	33.95
Weighted-Average Exercise Price Per Share, Options expired	25.56	98.69
Weighted Average Exercise Price Per Share, Outstanding Ending Balance	14.46	$ 21.60
Weighted Average Exercise Price Per Share, Vested and expected to vest	15.03
Weighted Average Exercise Price Per Share, Exercisable	$ 22.20
Aggregate Intrinsic Value, Outstanding Balance	$ 240	$ 305
Aggregate Intrinsic Value, Vested and expected to vest	$ 240

Stock-Based Compensation and _5

Stock-Based Compensation and Employee Stock Purchase Program - Weighted-Average Fair Value Assumption of Stock Option Awards (Detail) - Employee Stock Option [Member]	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	6 years 5 months 23 days	7 years 14 days
Expected volatility	134.00%	99.00%
Risk-free interest rate	1.01%	2.01%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Aug. 21, 2020USD ($)Installmentshares	Dec. 31, 2010USD ($)Program	Dec. 31, 2020USD ($)Installmentshares	Dec. 31, 2019USD ($)	Jun. 15, 2005USD ($)
Commitments And Contingencies [Line Items]
Other noncurrent liability			$ 2,280,000	$ 2,000,000
Milestones payments yet to be achieved			2,000,000	2,000,000
Milestones payment			0	0
Accounts Payable and Accrued Expenses [Member]
Commitments And Contingencies [Line Items]
Royalties due to both related and unrelated parties on license revenue accrued			$ 356,000	266,000
Anawah, Inc [Member]
Commitments And Contingencies [Line Items]
Contingent liability		$ 3,000,000			$ 5,000,000
Date of merger and reorganization			Jun. 15, 2005
Restructuring activities, description			As of December 31, 2010, the Company ceased activities relating to three of the six Anawah product programs
Number of development programs ceased \| Program		3
Number of development programs \| Program		6
Other noncurrent liability			$ 2,000,000
Gain on abandon of technologies				$ 1,000,000
Industrial Seed Innovations [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract			3 years
Remaining amount paid in multiple installments	$ 280,000		$ 280,000
Number of installment become due within 12 months as full amount contingent consideration included in other noncurrent liabilities \| Installment			0
Industrial Seed Innovations [Member] \| Common Stock [Member]
Commitments And Contingencies [Line Items]
Number of annual installment of common stock shares payable \| Installment	2		2
Minimum [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract			1 year
Royalty payments due, percentage of net revenue as defined in the In-Licensing agreements			2.00%
Maximum [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract			5 years
Royalty payments due, percentage of net revenue as defined in the In-Licensing agreements			15.00%
Maximum [Member] \| Industrial Seed Innovations [Member] \| Common Stock [Member] \| Revenue Milestone in 2021 [Member]
Commitments And Contingencies [Line Items]
Business combination, equity interest issuable upon achievement of revenue milestone \| shares	132,626		132,626
Maximum [Member] \| Industrial Seed Innovations [Member] \| Common Stock [Member] \| Revenue Milestone in 2022 [Member]
Commitments And Contingencies [Line Items]
Business combination, equity interest issuable upon achievement of revenue milestone \| shares	132,626		132,626

Leases - Additional Information

Leases - Additional Information (Detail) $ in Thousands	1 Months Ended	12 Months Ended
Leases - Additional Information (Detail) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020USD ($)Lease	Apr. 30, 2020Lease	Dec. 31, 2019USD ($)
Lessee Lease Description [Line Items]
Sublease, description of option to extend		lease amendments, including one that provides for additional office space in Davis, CA, and extends the term through April 2025, with one option to renew for an additional five-year term. The Company expects to exercise its options to renew, and in accordance with ASC 842, accounted for the amendment and expected renewal as a lease modification and remeasured the operating lease liability
Number of lease amendments \| Lease		4	2
Operating Lease, Liability		$ 6,106		$ 2,108
Right of use assets		$ 5,826		$ 1,963
Existence of option to extend		true
Lease option to extend, description		Some leases (the Davis office, warehouse, greenhouses and a copy machine) include one or more options to renew, with renewal terms that can extend the lease term from one to six years.
Minimum [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term		1 year
Operating leases, term of contract		1 year
Maximum [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term		6 years
Operating leases, term of contract		5 years
ASU 2016-02
Lessee Lease Description [Line Items]
Operating Lease, Liability		$ 3,800
Right of use assets		$ 3,800
Molokai, HI, [Member]
Lessee Lease Description [Line Items]
Sublease, description of option to extend		lease amendment for additional parcels of land in Molokai, HI, modified the Molokai office space lease to extend the term by 12 months, and entered into new lease agreements for office equipment, collectively resulting in an additional $0.1 million of operating lease liabilities and right of use assets.
Operating Lease, Liability		$ 100
Right of use assets		$ 100
Woodland, CA, [Member]
Lessee Lease Description [Line Items]
Sublease, description of option to extend		lease amendment for the land and greenhouses in Woodland, CA, extending the term by four years collectively, and resulting in an additional $0.3 million of operating lease liabilities and right of use assets.
Operating Lease, Liability		$ 300
Right of use assets		$ 300
Oregon [Member]
Lessee Lease Description [Line Items]
Sublease, description of option to extend		In connection with the ISI Acquisition, the Company entered into a new lease for the premises and equipment in Oregon with a three-year term, resulting in an additional $0.2 million of operating lease liabilities and right of use assets.
Operating Lease, Liability		$ 200
Right of use assets		$ 200
Oregon [Member] \| Premises And Equipment [Member]
Lessee Lease Description [Line Items]
Operating leases, term of contract		3 years
Office Space [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term		5 years
Office Space [Member] \| Molokai, HI, [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term		12 months
Office Space [Member] \| Woodland, CA, [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term		4 years
Office Space [Member] \| Chesterfield, MO [Member] \| Scenario Forecast [Member]
Lessee Lease Description [Line Items]
Operating leases, term of contract	38 months
Existence of option to extend	false

Leases - Schedule of Leases (De

Leases - Schedule of Leases (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Assets
Operating lease assets	$ 5,826	$ 1,963
Total leased assets	5,826	1,963
Liabilities
Current - Operating	717	611
Noncurrent - Operating	5,389	1,497
Total leased liabilities	6,106	2,108
Lease Cost
Net lease cost	$ 1,302	$ 858
Lease Term and Discount Rate
Weighted-average remaining lease term (years)	5 years	2 years 7 months 6 days
Weighted-average discount rate	6.00%	7.00%
SG&A and R&D Expenses [Member]
Lease Cost
Operating lease cost	$ 1,042	$ 708
Sublease income	(45)	(55)
R&D Expenses [Member]
Lease Cost
Short term lease cost	$ 305	$ 205

Leases - Schedule of Maturities

Leases - Schedule of Maturities of Operating Lease Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Lessee Disclosure [Abstract]
2021	$ 1,089
2022	962
2023	927
2024	817
2025	782
Thereafter	3,396
Total operating lease payments	7,973
Less: imputed interest	1,867
Total current and noncurrent operating lease liabilities	$ 6,106	$ 2,108

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)	Feb. 26, 2021	Jun. 26, 2020	May 18, 2020	Apr. 16, 2020	Dec. 31, 2020
Promissory Note [Member] \| Paycheck Protection Program [Member]
Debt Instrument [Line Items]
Interest rate				1.00%
Debt instrument, face amount				$ 1,100,000
Debt instrument maturity date				Apr. 16, 2022
Debt instrument, frequency of periodic payment				monthly
Debt instrument, prepayment penalty				$ 0
Debt instrument outstanding amount					$ 1,100,000
Promissory Note [Member[ \| MidFirst Bank [Member]
Debt Instrument [Line Items]
Interest rate			2.50%
Debt instrument maturity date			May 18, 2023
Debt instrument outstanding amount					2,000,000
Line of credit facility initiation date		Jun. 26, 2020
Line of credit facility maximum borrowing capacity		$ 2,000,000
Line of credit facility agreement date			May 18, 2020
Debt instrument interest rate terms			Pursuant to the Loan Agreement, the Note accrues interest, adjusted monthly, at a rate equal to the greater of (i) 3.25% and (ii) the sum of (a) the quotient of the LIBOR Index divided by (one minus the reserve requirement set by the Federal Reserve), and (b) 2.50%.
Promissory Note [Member[ \| MidFirst Bank [Member] \| Subsequent Events [Member]
Debt Instrument [Line Items]
Repayments of line of credit	$ 2,000,000
Promissory Note [Member[ \| MidFirst Bank [Member] \| Restricted Cash [Member]
Debt Instrument [Line Items]
Deposit account					$ 2,000,000
Vehicle Loans [Member]
Debt Instrument [Line Items]
Debt instrument maturity year					2024
Loans					$ 138,000
Minimum [Member] \| Promissory Note [Member[ \| MidFirst Bank [Member]
Debt Instrument [Line Items]
Interest rate			3.25%
Minimum [Member] \| Vehicle Loans [Member]
Debt Instrument [Line Items]
Interest rate					7.64%
Maximum [Member] \| Promissory Note [Member[ \| MidFirst Bank [Member]
Debt Instrument [Line Items]
Line of credit facility maximum borrowing capacity			$ 2,000,000
Maximum [Member] \| Vehicle Loans [Member]
Debt Instrument [Line Items]
Interest rate					8.00%

Debt - Schedule of Maturities o

Debt - Schedule of Maturities of Current and Noncurrent Debt (Detail) $ in Thousands	Sep. 30, 2020USD ($)
Lessee Disclosure [Abstract]
2021	$ 1,141
2022	32
2023	2,035
2024	38
Total	$ 3,246

Income Taxes - Components of Lo

Income Taxes - Components of Loss Before Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Domestic	$ (6,150)	$ (28,871)
Foreign	0	0
Loss before income taxes	$ (6,150)	$ (28,871)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
Income Taxes - Additional Information (Detail) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Schedule Of Income Tax [Line Items]
Total income tax expense (benefit)	$ (124,000)	$ 2,000
Increase (decrease) in net valuation allowance	$ 1,900,000	$ (25,900,000)
Operating loss carryforwards limitations on use	it has not forfeited the right to carryforward tax losses up to 20 years
Tax years subject to examination to extent of NOLs being carried forward	2001
Maximum [Member]
Schedule Of Income Tax [Line Items]
Right to carryforward tax losses, period	20 years
Tax year subject to examination by the tax authorities	2020
Minimum [Member]
Schedule Of Income Tax [Line Items]
Tax year subject to examination by the tax authorities	2001
Federal [Member]
Schedule Of Income Tax [Line Items]
Aggregate amount of net operating loss	$ 55,800,000
Operating loss carryforward generated	193,100,000
Operating loss carryforward unutilized	7,200,000
Operating loss carryforward expected to be unavailable	130,500,000
State [Member]
Schedule Of Income Tax [Line Items]
Aggregate amount of net operating loss	$ 57,200,000

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Tax Expense Comprised of Current State Taxes and Foreign Taxes (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Current:
Federal	$ 0	$ 0
State	(28,000)	2,000
Foreign	10,000	0
Total current tax (benefit) expense	(18,000)	2,000
Deferred:
Federal	(84,000)	0
State	(22,000)	0
Foreign	0	0
Total deferred tax (benefit) expense	(106,000)	0
Total tax (benefit) expense	$ (124,000)	$ 2,000

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Statutory Federal Income Tax Rate to the Company's Effective Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Expected income tax provision at the federal statutory rate	21.00%	21.00%
State taxes, net of federal benefits	9.40%	5.30%
Change in valuation allowance	(43.80%)	(26.40%)
Transaction costs	(2.20%)	0.00%
Related offering costs	0.00%	(0.50%)
Derivative liabilities	22.40%	0.00%
Non-Controlling Interest	(4.70%)	0.00%
Withholding taxes	(0.20%)	0.00%
Other	0.00%	0.60%
Income tax provision	1.90%	0.00%

Income Taxes - Summary of Compa

Income Taxes - Summary of Company's Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Deferred tax assets:
Net operating loss carryforwards	$ 15,478	$ 13,267
Unearned revenue	2	11
Stock-based compensation	3,881	3,384
Accrued payroll and benefits	236	224
Research and development credits	16	0
Fixed asset basis difference	84	90
Inventory reserve	491	568
Lease liability	1,622	565
Common stock warrant assets	0	988
Contingent Consideration	531	0
Charitable contributions	3	2
Total deferred tax assets	22,344	19,099
Deferred tax liabilities:
Right of use asset	(1,548)	(526)
Amortizable intangibles	(98)	0
Income from Partnerships	(13)	0
Other	(174)	0
Total deferred tax liabilities	(1,833)	(526)
Less valuation allowance	(20,511)	(18,573)
Net deferred tax assets	$ 0	$ 0

Income Taxes - Schedule of Unre

Income Taxes - Schedule of Unrecognized Tax Benefits (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Income Tax Disclosure [Abstract]
Increases for tax positions taken in prior years	$ 2
Increases for tax positions taken in current years	15
Unrecognized tax benefit ending balance	$ 17

Retirement Benefits - Additiona

Retirement Benefits - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Compensation And Retirement Disclosure [Abstract]
Employer matching contribution, percent	50.00%
Maximum annual contribution per employee, percent	3.00%
Description of defined contribution pension and other postretirement plans	Employees’ rights to employer contributions vest on the one-year anniversary of their date of employment.
Defined benefit plan employee vested minimum period, years	1 year
Amount accrued for company's approved discretionary match	$ 0	$ 0

Segment and Geographic Informat

Segment and Geographic Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2020Segment
Segment Reporting [Abstract]
Number of operating segment	1

Segment and Geographic Inform_2

Segment and Geographic Information - Summary of Revenues Based on Location of Customers (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	$ 8,034	$ 1,169
United States
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	761	722
Argentina
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	6,681
India
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	100	7
Africa
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	106	182
Canada
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	354	$ 258
Austria
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	$ 32

Net Loss per Share - Summary of

Net Loss per Share - Summary of Securities Not Included in Diluted Per Share Calculations (Detail) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	8,090,039	4,832,352
Option to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	889,759	661,701
Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	7,200,280	4,170,651

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail)	1 Months Ended			12 Months Ended
	Apr. 30, 2020USD ($)aLease	Mar. 31, 2020USD ($)a	Feb. 28, 2019USD ($)a	Dec. 31, 2020USD ($)Leaseshares	Dec. 31, 2019USD ($)
Related Party Transaction [Line Items]
Royalty fees due				$ 80,000	$ 40,000
Number of lease amendments \| Lease	2			4
Lease payments				$ 84,000	84,000
Stock-based compensation				2,042,000	2,287,000
Mr. Kevin Comcowich [Member]
Related Party Transaction [Line Items]
Acres of land \| a			10
Operating leases, term of contract			2 years
Rent payments			$ 1,200
Out of pocket costs					126,400
Payments received from contractor					44,000
Stock-based compensation				$ 9,000
Lease expiration date				Feb. 28, 2022
Number of parcels of leased land \| Lease				5
Options issued to purchase common stock \| shares				5,273
Mr. Kevin Comcowich [Member] \| Amendment [Member]
Related Party Transaction [Line Items]
Acres of land \| a	15	10
Operating leases, term of contract	2 years	2 years
Number of additional properties under lease agreement	two additional 15-acre parcels	two additional 10-acre parcels
Rent payments	$ 1,200	$ 1,200
John Sperling Foundation [Member]
Related Party Transaction [Line Items]
Royalty fees due				$ 80,000	$ 40,000

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - Subsequent Events [Member] - Securities Purchase Agreement [Member] $ / shares in Units, $ in Millions	Jan. 25, 2021USD ($)$ / sharesshares
Subsequent Event [Line Items]
Cash proceeds, net of transaction fees \| $	$ 23.3
Institutional and Accredited Investors [Member]
Subsequent Event [Line Items]
Shares of common stock issued	7,876,784
Warrant issued, shares of common stock called by warrant	3,938,392
Stock price \| $ / shares	$ 3.1925
Warrants expiration period	5 years 6 months
Warrants issued, exercise price \| $ / shares	$ 3.13
Wainwright or Designees [Member]
Subsequent Event [Line Items]
Warrant issued, shares of common stock called by warrant	393,839
Maximum [Member] \| Wainwright or Designees [Member]
Subsequent Event [Line Items]
Percentage of warrants to purchase aggregate number of shares	5.00%